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Abstract 
Breast cancer is a malignant tumor, commonly found in women but rarely in men. One in 
eight US women will have the chance of developing breast cancer in their lifetime.  A family 
history analysis and genetic test can identify the potential carrier gene that cause hereditary 
breast cancer. Mutated genes such as BRCA1, BRCA2, Tp53 and PTEN confer high lifetime risk 
of breast cancers and are the most significant genes for clinical studies. The study goals of this 
thesis were to: 1) develop an open source software tool to predict the risk of hereditary breast 
cancer and mutation risk of breast cancer in any person, 2) predict the risk of hereditary breast 
cancer in the next generation by analyzing the inheritance patterns of the genes, and 3) exploit 
medical guidelines and connect it with information technology.  
In the program, we combine National Comprehensive Cancer Network (NCCN) 
guidelines of BRCA1/BRCA2, TP53, and PTEN gene mutations. We have sought the help of 
medical practitioners, medical literatures, and all other credential reports to validate the output of 
this research.  The input data for this program are family history and other cancer risk assessment 
guidelines for the individual. We have developed this software tool in C++ and JavaScript. In the 
program, we identify a person’s family history, age, and gender through questionnaires and make 
an evaluation of different possibilities and outcome. We analyze the risk of mutation with the 
help of family history. We have considered first, second, and third-degree relatives and 
individuals who belong to Ashkenazi Jewish ancestry.   
After the analysis, and if the person is at risk, we predict the mutation risk of the next 
generation based on the gene’s inheritance pattern. This tool would help the members of the 
general public who have the least knowledge about breast cancer and genetic inheritance, and it 
would also help them to identify the presence of mutated genes.
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1 CHAPTER 1 
Introduction 
Medical data that is stored in computers present many promising advantages in medical 
research. Nowadays, medical reports and health information are becoming more available as the 
generations pass. Therefore, research that exploits medical data brings new advancements in 
medical systems. In this computer-driven world, genome mapping and medical technology have 
made it possible to get genetic information at low cost, which was not possible earlier. Advances 
in computer processing and medical technology made it possible to get a genome mapping of 
any person quickly. We can exploit these advancements to assess a person’s risk factors for any 
given diseases that are inherited or related to a genetic defect.  The Human Genome Project 
(HGP) is an international scientific research project with a primary goal of determining the 
sequence of chemical base pairs, which make up human DNA (Williams, 1997). It took efforts of 
several international institutes to complete, and remains the world’s largest collaborative 
biological project. The HGP has identified about 20,500 human genes and provides information 
about the structure and whole functions of human genes. As the years go by, family health 
history stored in computers provides better assessments, accuracy, and standardization in 
forecasting diseases. Combining all known diseases, symptoms, and diagnoses helps medical 
practitioners to determine and forecast diseases in the current or next generations. Computers 
could be trained to forecast and predict specific diseases. 
A family history gives a report about a person and his or her relatives (Agrawal, 
Suleiman, Seay, & Gloster, 2013). Families have many common factors, such as genes, lifestyle, 
environment and ethnic background. These common factors can be related to some medical 
conditions that run in a family. We can use genetic reports, family medical history, medical 
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reports, and lab reports to forecast a person’s probability of getting diseases that are inherited. 
Getting genome mapping helps to diagnose some hereditary diseases.  Even though, we cannot 
change the existing gene pattern, we can be informed and take precautions based on the available 
reports. Integrating medical, family, and genetic reports will help to predict hereditary diseases 
such as cancer, diabetics, and asthma. Furthermore, study and research about cancer is on the rise 
for various reasons. The World Health Organization estimates significant growth in cancer 
patients worldwide, and cancer is poised to overtake heart disease as the world’s top killer. There 
are about two hundred cancers known at this time. The primary factor in cancer is the 
uncontrollable growth of cells. Cancer screening can be used to detect early symptoms of cancer. 
There are different reasons for cancer, and the primary reason is environmental factors, which 
include tobacco use, diet, obesity, infections, radiations, stress, lack of physical activity, and 
pollutants. Everyone has the risk of developing cancer in his or her lifetime. The factors behind 
developing cancer include age, lifestyle, chemicals, radiation, genetics, immune system, and 
infection. Most of the cancers are non-hereditary, and inherited genetic defect commonly causes 
hereditary cancers. Hereditary cancer is associated with highly penetrant genes, and pass to the 
next generation through different inheritance patterns. Hereditary cancer can be predicted earlier 
based on a pedigree analysis. A pedigree is a chart or diagram of family history analysis that 
includes parents, grandparents, and previous generations, and it checks the occurrence of any 
inherited diseases. The information collected from pedigree analysis is useful to determine the 
cancer risk for an individual or his/her progeny.  
Cancer can be predicted in current or future generations based on the information 
gathered from family history tools, genetic and medical guidelines. Family health history plays 
an important role in determining the risk factors as it gives a link to hereditary, environmental, 
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cultural, and behavioral factors of the entire family (Aiello-Laws, 2011). The risk can be 
considered high, moderate, and average, based on the number of the family affected and age at 
the onset of the people who are affected in the family (Yoon et al., 2002). In this thesis, we have 
focused on predicting the risk of mutated genes that cause breast cancer, as most of the 
hereditary cancers are predictable at early stages. 
Breast cancer can occur in both men and women, but it is far more common for women. 
A family history analysis and genetic test can identify the potential carrier gene behind breast 
cancer. Breast cancer is a malignant tumor which is capable of spreading into surrounding tissues 
or to distant areas. The risk factors involved with breast cancers are age, gender, genetic factors, 
family history, race/ethnicity, and habits. Breast cancer occurs in more often in females than in 
males because of the female hormones like estrogen and progesterone, which help cancer cell 
growth. The risk of developing breast cancer increases with age. Mutated genes such as BRCA1, 
BRCA2, PTEN, and Tp53 make the individual at high lifetime risk of breast cancer (Cancer 
Research UK, 2014). There are other genes such as PALB1, BRIP and LKB1 behind breast 
cancer, which contribute moderate risk. However, BRCA1, BRCA2, TP53, and PTEN are the 
genes considered most for clinical studies (Allain, 2008).  The rest of the paper is organized as 
follows: Section 1.2 discusses the problem statement, and motivation for this thesis and Chapter 
2 presents literature review. Chapter 3 explains different breast cancer prediction models 
available to predict cancer. Chapter 4 provides details about the analysis of hereditary 
information in predicting breast cancer. Chapter 5 explains the prediction of hereditary breast 
cancer risk in current and next generations, and Chapter 6 discusses future work. 
5 
 
 
1.1 What is Cancer? 
Cancer is a general term used to define abnormal cell division, and it attacks other 
tissues. Cancer spreads into the body through the blood and lymphatic systems. The cell is the 
basic unit of our bodies. All living things are made up of cells. The human body is made up of 
different kinds of cells. Different cells have different functions in the body (Williams, 1997). 
Like other living things, cells die, and new cells will be produced by the body. Normally cells 
divide faster in early ages and allow the body to grow. After a person reaches adulthood, cell 
division happens only to replace the dying cells.  
DNA is the genetic material of a cell, and it controls growth and cell division. Sometimes 
when the DNA becomes damaged, cell division and growth go out of control, and that can lead 
to accumulations of extra cells called tumors. Abnormal cells or cancer cells can spread to other 
body parts through the blood or lymphatic systems. Spreading cancer into other parts of the body 
is called metastasis (National Cancer Institute [NCI], 2015). Not all tumors are cancerous. 
Tumors can be divided into two types, benign tumors, and malignant tumors. Benign tumors are 
not cancerous and do not invade other parts of the body. Malignant tumors are cancerous, and 
they are able to attack other parts of the body. Cancers can be divided into different categories, 
and the main categories are as follows: 
 Carcinoma: Cancer that begins in the skin or in the tissues that cover the other organs in 
the body is called carcinoma cancer. 
 Sarcoma: Cancer that originates from bone, fat, muscle, blood vessels, cartilage, or other 
connective tissues is called sarcoma.  
 Leukemia: Cancer that begins in the bone marrow is known as leukemia. Bone marrow is 
a blood-forming tissue, found in the center of the bones, and it produces blood cells. 
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 Lymphoma and Myeloma: These are cancers that affect the immune system. 
 Central nervous system cancers: These are cancers that are related to the brain and spinal 
cord (NCI, 2015). 
The cancer risk assessment can be used to determine the level of risk for each individual. 
Many family history factors can give details about cancer risk. Identifying cancer with genetic 
testing can be used for treatment and for other prevention methods for patients. Therefore, cancer 
risk assessment and testing can be useful in personalizing therapies to improve the outcomes of 
the treatments (Riley et al., 2012). Cancer risk assessment is composed of many factors, 
including personal and family health history, reproductive history and hormone use, 
environmental risk factors, lifestyle and genetic information (Aiello-Laws, 2011). An accurate 
risk assessment directs the proper use of cancer screening, risk reduction, genetic testing and 
early detection strategies. It is also important to asses a complete medical and surgical history, 
including current medications, lifestyle, environmental exposures, and congenital anomalies. If 
the patient is a female, a detailed reproductive history is needed (Aiello-Laws, 2011). In order to 
get a detailed assessment, we can use pedigree analysis, genetic testing, risk modeling, 
biochemical testing and imaging, physical features, potential hereditary syndromes and cancer 
risk assessment for a patient’s biological relatives. The information gathered can be used for 
cancer screening, prevention, and risk reduction, and also for identifying cancer at-risk family 
members (Riley at al., 2012). 
1.2 What is Breast Cancer? 
Breast cancer is a cancer that is found in breast cells. It is commonly found in women and 
rarely in men. Female breasts are made up of milk-producing glands, lobules, and ducts that 
carry milk from lobules to nipples. Ducts and lobules are covered with fatty connective tissue 
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called stroma. Breast cancer that begins in the tissues of ducts is called ductal cancers, and 
cancer that begins in the tissues of lobules is known as lobular cancer (American Cancer Society, 
2014). Breast cancer can spread to other body parts through the lymphatic system. Lymph cells 
are immune system cell that helps the cells to fight infections and foreign materials that enter the 
body. A lymphatic system consists of lymph cells, lymph fluid, and lymph vessels that carry the 
lymph around the body. Breast cancer cells are able to invade the lymph vessels and begin to 
grow in the lymph nodes. The lymph vessels carry these cancerous cells to the other part of the 
body, which is known as metastatic or secondary cancer (American Cancer Society, 2014). 
The risk of developing breast cancer in women increases with their ages. The other 
factors that increase the risk are hormone replacement factors, which include the use of hormone 
replacement therapy (HRT), hormonal contraceptives, obesity, and alcohol. The risk is reduced 
by different factors, which are being a young age at first childbirth, breast feeding, late menarche 
and early menopause. The risk will double if the women have an affected first-degree relative 
compared to women who don’t have a family history of breast cancer. High penetrance genes 
such as BRCA1 and BRCA2 contribute high risk but only account for a small percentage of 
breast cancer. The lifetime risk of breast cancer with BRCA1 accounts for 85%, and ovarian 
cancer accounts 40% (Murray & Davies, 2013). However, the BRCA2 pathogenic variant shows 
a little lower risk, especially for ovarian cancer, and it accounts less than 20%. For males BRCA 
mutations contribute a risk for prostate cancer and breast cancer that is only 6 % (Murray & 
Davies, 2013). Genetic information or family history can be identified using a family tree 
diagram or pedigree analysis. Patients are assigned to one of the risk categories; women at or 
near population risk of developing breast cancer, women at raised risk of developing breast 
cancer and women at high risk of developing breast cancer. Many factors can be found in family 
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histories that are suggestive of BRCA pathogenic variant. The clues include, multiple individuals 
on one side of the family with breast or ovarian cancer, a young average age of diagnosis, male 
breast cancer, associated cancer, and individuals with more than one primary cancer, including 
bilateral breast cancer, and Ashkenazi Jewish Ancestry (Murray & Davies, 2013). 
1.2.1 Factors that decrease the risk. The main risk factors that affect breast cancer 
include age, gender, and mutation in breast cancer genes. A woman who started her first 
menstrual period before the age of 12 is slightly at risk for breast cancer. The three hormones 
that affect any woman in monthly menstrual cycles are estrogen, testosterone, and progesterone. 
Estrogen level will be high in the body during the week of the menstrual cycle. Estrogen level 
will be low after the menstrual days. Exposure of breast tissue to increased levels of estrogen 
makes the women more at risk of developing breast cancer. Consequently, starting menstrual 
period at an early age increases the risk of breast cancer (Centers for Disease Control and 
Prevention [CDC], 2014). 
Before menopause, estrogen is produced by the ovaries, and after menopause, estrogen 
will be produced by fat tissue. Women who have menopause at an early age are less exposed to 
estrogen. Giving birth to more children, giving birth to your first child at a young age, and 
breastfeeding your children can also decrease the risk. Pregnancy and breast-feeding reduces the 
risk of breast cancer as it reduces the women’s lifetime exposure to menstrual cycles and hence, 
reduces exposure to estrogen level. Physical activity lowers the level of estrogen in the blood and 
boosts the immune system of the body. Becoming obese after menopause may increase the risk 
of breast cancer, as it increases the risk of estrogen receptor-positive breast cancer (CDC, 2014). 
1.2.2 Factors that increase the risk. Long-term use of hormone replacement therapy: 
Women use hormone replacement therapy to ease menopause. The hormones commonly 
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prescribed in the therapy are estrogen and progesterone or progestin. Studies show that a woman 
taking HRT has a high risk of developing breast cancer. If you have ever been diagnosed with 
breast cancer, the recurrence of cancer in another part of the breast is always high. If you have 
first-, second-, or third-degree relatives diagnosed with breast cancer, the risk of inheriting the 
mutated gene is always possible, and that makes you at risk. In rare cases, radiation can cause 
secondary breast cancer. Diethylstilbestrol is a form of estrogen hormone. This hormone was 
prescribed to women to avoid miscarriage, premature labor, and related pregnancy problems 
between 1940 and 1971. Different studies (Palmer et al., 2002) show that the women who have 
received DES are more at risk of breast cancer when compared with women who never had DES. 
Women who have high breast density are more at risk than women who have less breast density 
(CDC, 2014). Alcohol increases the level of estrogen and other hormones relate to hormone-
receptor- positive breast cancer. During the night, our body produces the hormone melatonin that 
makes us feel sleepy and want to a rest. Exposure to artificial light, during the night, may reduce 
the level of melatonin. As a result, it causes the body to produce more estrogen and makes 
people at risk of breast cancer. 
1.3 Problem Statement 
According to Mayo Clinic, after skin cancer, breast cancer is the most common cancer 
diagnosed in women in the United States. We have chosen breast cancer mutation risk, as breast 
cancer is considered one of the leading causes of cancer deaths in women. As a common cancer 
in women, are we able to predict the risk of carrying mutated genes based on the family history? 
Family history can be considered one of the important risk factors for many chronic diseases. 
The cancer risk assessment includes a complete personal medical history and previous 
generations’ medical history to the extent that they are available. Family history helps to identify 
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higher risk for some diseases and also helps to get an idea about early warning signs of diseases.  
Does family history play an important role in predicting hereditary cancers? There are different 
models available to the public to check breast cancer risk. Can we completely depend on these 
prediction models to analyze the mutation risk? Do these models analyze complete family 
history and other non-hereditary factors that affect sporadic breast cancer such as birth control, 
hormone therapy, breastfeeding, drinking alcohol, and physical activity? In hereditary breast 
cancer, the gene passes to the next generation through an autosomal dominant inheritance 
pattern. Every child inherits two copies from their parents; one from their mother and one from 
the father. As BRCA1, BRCA2, Tp53, and PTEN genes exhibit autosomal inheritance pattern; 
there are four possible combinations for the child’s gene copy. By analyzing the inheritance 
patterns, how can we predict the risk of carrying mutated genes in the offspring?  
The aim of this research is to develop a software tool to predict the risk of hereditary 
breast cancer in any living person and also in their children. The backbone of this software 
program is NCCN guidelines. The existing tools to check the hereditary breast cancer are only 
considering BRCA1/BRCA2 genes. Some of the tools are not considering family history.  In this 
research, we have included PTEN and Tp53 genes and also considered first-, second-, and third-
degree relatives. NCCN guidelines are the most thorough, comprehensive, up-to-date, and 
reliable recommendations and are from a group of worldwide clinical practitioners.  
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2 CHAPTER 2  
Literature Review 
2.1 Recent Breast Cancer Statistics  
There are more than two hundred types of cancers that are recognized in the human body. 
Nowadays, study and research about cancer is on the rise for various reasons. The World Health 
Organization estimates significant growth in cancer patients worldwide and that cancer is poised 
to overtake heart disease as the world’s top killer. According to the American Cancer Society, 
the most common type cancer is breast cancer, with about 235,000 new cases expected in the 
United States in 2014 (American Cancer Society, 2015). The following table shows the 
estimated numbers of new cases and death for each common cancer. 
Table 1  
Breast Cancer Statistics 
Cancer Type Estimated New Cases Estimated Deaths 
Bladder 74,690 15,580 
Breast (Female – Male) 232,670 – 2,360 40,000 – 430 
Colon and Rectal (Combined) 136,830 50,310 
Endometrial 52,630 8,590 
Kidney (Renal Cell and Renal 
Pelvis) Cancer 
63,920 13,860 
Leukemia (All Types) 52,380 24,090 
Lung (Including Bronchus) 224,210 159,260 
Melanoma 76,100 9,710 
Non-Hodgkin Lymphoma 70,800 18,990 
12 
 
 
Table 1 
Cont. 
Pancreatic 46,420 39,590 
Prostate 233,000 29,480 
Thyroid 62,980 1,890 
  
In the United States 12% (one in eight) of women are at risk of invasive breast cancer 
during their lifetime (Breastcancer.org, 2014). About 62,570 new cases of non-invasive breast 
cancer have been reported in the United States. Breast cancer incidence rate was decreased from 
the year 2002 to 2003 after the decrease in the use of hormone replacement therapy. The study 
shows a large decrease in the death rate after 1989, and it is thought to be the result of early 
detection and prevention. However, the death rate is higher than any other cancer except lung 
cancer. White women have more probability to develop breast cancer than African American 
women. However, breast cancer under the age of 45 is more prevalent in African American 
women than white women. Asian, Native American, and Hispanic women have a lower risk of 
developing breast cancer. In 2014, recent data shows 2.8 million women are identified with 
breast cancer, which includes women who are undergoing treatment and who finished treatment. 
Among women with breast cancer, 15% have a family history of breast cancer (American Cancer 
Society, 2015).  
2.2 Open Source Cancer Risk Assessment Tools 
There are many software programs available to assess breast cancer risk and screening. 
Early detection of breast cancer helps to make a decision about the prevention of the cancer. 
None of the tools are accurate. However, it gives an understanding of breast cancer risk based on 
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your habits and family history. These programs have many features and limitations. One of the 
main drawbacks of all the programs is, none of the tool takes all risk factors associated with 
breast cancer. Each tool calculates only an estimated result based on the risk factors it considers. 
As there is no comprehensive breast cancer risk assessment tool, it is advisable to consider other 
health care assist to detect breast cancer earlier. Before checking the risk, try to use a reliable and 
credible program that has been created by a faithful source. Select a tool that provide the features 
and limitations of the tool, and understand how it was developed.  
2.2.1 Gail model – Breast cancer risk assessment tool. This program has been 
developed (http://www.cancer.gov/BCRISKTOOL/) by scientists at the National Cancer Institute 
(NCI) and it is periodically updated with new data. The Gail model is used to calculate invasive 
breast cancer risk over a five year period and a lifetime period (Gail et al., 1999). This tool is 
useful for healthcare providers to assess the breast cancer risk and also help to make decisions in 
prevention strategies. This tool mainly focuses on non-genetic factors, personal history, previous 
breast biopsies, age of menarche, age of first live birth and family history of first-degree 
relatives. The main drawbacks of the program are, it does not consider other breast cancer-
related factors such as breast density, hormone replacement therapy, breastfeeding, smoking, age 
at menopause and alcohol consumption. 
2.2.2 IBIS tool. The IBIS tool (http://www.ems-trials.org/riskevaluator/) is used to 
calculate a person’s likelihood of carrying the BRCA 1 or 2 mutations, which are associated with 
increased breast cancer risk. It estimates the likelihood of a woman developing breast cancer in 
ten years and over the course of her lifetime. The tool is used to help inform a person’s decision-
making about genetic counseling and testing.  
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The IBIS tool is developed based on the Tyrer-Cuzick model and it predicts a person’s 
risk of carrying BRCA1 or BRCA2 genes. It calculates the risk of developing breast cancer over 
ten years and a lifetime period based on the estimation of BRCA1/BRCA2 genes. It is a good 
breast cancer decision-making tool. It considers many risk factors such as age, age at first live 
birth, body mass index, hormone replacement therapy, age at menopause, and family history. 
This tool suggests genetic counseling if the risk is 10% or higher. The disadvantages of the tool 
are that it does not consider breast density, alcohol consumption, oral contraceptive pill use, etc.  
2.2.3 Myriad II. Myriad II (http://www.myriadpro.com/brca-risk-calculator/calc.html) 
has been developed based on empirical data which was conducted among ten thousand women 
with germline mutations in BRCA1/BRCA2 genes. The Myriad II prevalence tables (Frank et al., 
1998) are based on proband and family history (van et al., 2010). The tool considers different 
risk factors such as relatives with ovarian cancer at any age, relatives with breast cancer, age of 
the relatives, and male breast cancer. It allows only a maximum of three relatives and does not 
give separate result for BRCA1 and BRCA2. It gives a separate analysis for Ashkenazi Jewish 
Ancestry.  
2.2.4 BOADICEA web application (BWA). The BOADICEA is another tool, and it has 
collaborated with MENDEL, (http://ccge.medschl.cam.ac.uk/boadicea/advice-for-the-public/) 
which is pedigree software used to estimate the risks of breast and ovarian cancer in women. It 
calculates the probability of BRCA1 or BRCA2 genes. It also predicts the possibility of a woman 
developing breast cancer in five years and in her lifetime. The tool uses family history and gene 
mutation risk to calculate the risk of breast cancer. The tool recommends genetic counselling if 
the risk is 10% or higher. This tool only considers mutation status and family history. It doesn’t 
consider any other non-genetic factors. The tool was developed based on data from the United 
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Kingdom. Therefore, the calculation will have less accuracy for other people from other 
countries. 
2.2.5 PENN II. It is a free web-based tool (http://www.afcri.upenn.edu/itacc/penn2/), and 
it uses logistic regression based on pedigrees from Europe and North America. The tool 
considers age at onset of breast cancer, ovarian cancer, bilateral breast cancer, pancreatic cancer, 
and prostate cancer. The results of the program contain both BRCA1 and BRCA2 mutations. The 
results don’t contain breast cancer risk, and it recommends genetic testing for people with 5% or 
higher risk. It gives a one-page questionnaire, and the tool considers first-, second-, and third-
degree relatives. It excludes proband from families with no breast cancer.  
2.2.6 Breast cancer surveillance consortium risk calculator. The Breast Cancer 
Surveillance Consortium (BCSC) risk calculator was created by scientists who participate in 
Breast Cancer Surveillance Consortium (https://tools.bcsc-scc.org/BC5yearRisk/intro.htm). This 
model gives a calculation of women’s risk over a five-year time period. The tool was designed 
for health care professionals. The tool does not consider previous diagnosis of breast cancer, 
lobular carcinoma in situ, ductal carcinoma in situ, atypical ductal hyperplasia, or breast 
augmentation. This tool only considers people who are between the ages of 35 and 79. The 
model focuses on age, race, ethnicity, family history of first-degree relatives, history of breast 
biopsy, and breast density. 
2.2.7 Hall detailed breast risk calculator. This open source breast cancer risk calculator 
was designed by Dr. Halls (http://halls.md/breast/risk.htm). This risk assessment tool includes 
many factors that are not included in the Gail model. This tool underestimates various factors 
such as two or more people in the same generation with the same cancer, breast cancer before the 
age of 50, ovarian cancer, cancers in both breasts, and melanoma. The tool includes first-degree 
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relatives, breast biopsies, age at menarche, age at first live birth, current age, and race. The result 
of the estimation falls into different categories. It gives the risk over five years, ten years, twenty 
years, thirty years, and a lifetime period.  
2.2.8 Bright Pink. Bright Pink is (http://www.brightpink.org/knowledge-is-
power/assess-your-risk/) another open source tool that calculates breast cancer risk. It is designed 
for academic use. This tool considers first- and second-degree relative breast cancer history, age 
at onset of breast cancer, multiple breast cancers, male breast cancer, ovarian cancer, other 
related cancers, and known mutations. The tool also considers non-genetic factors such as body 
mass index, alcohol consumption, smoking, physical activity, diet, birth control pills, and age at 
first live birth. The result is given in a PDF format. 
The above open source programs have many limitations. These tools are only considering 
BRCA1 and BRCA2 mutations. None of the existing breast cancer tools available considers 
other high-risk genes such as PTEN and Tp53. Many of the existing tools are proprietary and not 
available to the public. Most of these existing tools have been developed based on the data 
collected from a particular demography or ethnicity. Many of the tools available do not consider 
third-degree relatives and family history. 
2.3 Role of Family History in Breast Cancer Risk Assessment 
Family history can be considered one of the important risk factors for many chronic 
diseases. The cancer risk assessment includes a complete personal medical history and previous 
generations’ medical history to the extent that they are available. We have developed a family 
history diagram, as shown in Figure 1, with the help of the US Department of Health and Human 
Service website (HHS, 2014).  
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Figure 1. Family health portrait. 
The diagram helps a person to store his/her entire family history as a report or a diagram. 
The diagram assembles all information to make a pedigree analysis and give a family tree based 
on health records. It helps to identify the higher risk for some diseases and also helps to get an 
idea about early warning signs of diseases (HHS, 2014). This health information can be stored in 
HealthVault, and it will be accessible to the person at any time. In this project, this family history 
diagram makes it easy to develop the program based on pedigree analysis.  
Figure 1 describes the entire family history of a person that includes history of the 
deceased people and the reasons for death. It gives an overall idea about a person’s family health 
history that includes parents, grandparents, and first-degree relatives. It will be helpful to analyze 
if a person has any risk of cancer. If this family history diagram contains any repeated diseases 
among first-degree or second-degree relatives, the chances of getting the disease in the next 
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generation are high. Many family history factors can give details about hereditary diseases such 
as cancer, diabetics, heart attack, and asthma. 
Family history is an essential component of any cancer risk assessment. Family history 
tool must be simple, easily applied and inexpensive, and should be capable of identifying a 
person according with the intensity of the diseases and positively influencing healthy behaviors. 
When it comes to chronic diseases such as cancer and cardio vascular disease, family history 
reflects hereditary factors, environmental, cultural and behavioral factors (Yoon, Scheuner, & 
Khoury, 2003). A typical family history should be obtained from the proband. For each 
individual, specifically biological relationships among family members, ages, causes of death, 
genetics, surgical history, and any other medication should be marked. Hereditary cancer is 
associated with highly penetrant genes, and it reflects the range of risk associated with a 
mutation in the gene. Penetrance data from families with single gene mutation hereditary cancer 
syndromes are revised as modifier genes. Oncology professionals should reassess the family 
history, as family histories are dynamic. Accuracy of risk assessment can be affected by different 
factors (Aiello-Laws, 2011). The cancer risk assessment can be used to determine the risk level 
for each individual. Based on the family history, if an individual has a suggestive inherited 
cancer syndrome, a genetic testing can be carried out to detect the repeated cancer present in the 
family. The risk assessment includes a complete personal medical history and previous 
generations’ medical history, if available. A standardized pedigree nomenclature and well-
prepared questions are important factors in assessing the risk. Before starting questionnaires, 
preparing a family health history portrait of the individual will help in the risk assessment (Riley 
et al., 2012). Genetic tumor or cancer risk assessment reveals the possibility of DNA alterations, 
which are strong causes of cancer. Genetic risk assessment involves identifying and counseling 
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individuals at increased risk for cancer development and distinguishing the intensity of cancer. 
Genetic testing can be considered when an individual has a family history of genetic cancer 
susceptibility. Genetic testing is most useful when initiated when the person with cancer 
concerns is diagnosed at a young age. The test should begin by testing for the syndrome that the 
individual’s features most resemble (Aiello-Laws, 2011). In order to get a detailed assessment, 
we can use pedigree analysis of the entire family. The information gathered could be used for 
cancer screening, prevention, and risk reduction, and also for identifying cancer at-risk family 
members (Lalloo & Evans, 2012). 
Family health history is a significant cause that increases a person’s risk of developing 
breast and ovarian cancer. Every individual should be mindful of these risk factors in his/her 
family. In general, the number of first-, second-, or third-degree relatives who have or had breast 
or ovarian cancer, and the age at onset of their diagnosis, increases the person’s breast cancer 
risk. If you have a first-degree relative (sister, brother, father, son, or daughter) identified with 
breast cancer, the risk will be doubled (breastcancer.org, 2014). At the same time, if you have 
two first-degree relatives, the risk will be five times higher than the average. In many cases, 
family history of breast cancer is related to abnormal genes such as BRCA1, BRCA2, PTEN, and 
Tp53. 
Different studies among families show that many women developed breast and/or ovarian 
cancer together. A majority of the cases are reported at earlier than usual ages. Medical 
practitioners suggested the term Hereditary Breast and Ovarian Cancer Syndrome (HBOC) after 
the analysis in many families. The mutation in genes BRCA1 and BRCA2 are the main causes of 
this disease. Even though mutations in either gene can cause the risk, the BRCA1 mutation 
causes a higher risk of breast cancer. The BRCA2 mutation is more likely related to male breast 
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cancer, pancreatic cancer, and prostate cancer. The BRCA gene mutation is common in people 
who belong to Ashkenazi Jewish families. There are other hereditary diseases such as Cowden 
syndrome (gene Tp53 mutation) and Li-Fraumeni syndrome (PTEN gene mutation) that have a 
high impact on breast cancer (American Cancer Society, 2014). 
Women with a family history of breast/ovarian cancer can go through genetic counseling 
to calculate the risk of mutation in one of the BRCA genes. The professional will estimate the 
risk based on the personal or family history of cancer. After the estimation, if a mutation is 
present, the woman would have a high risk of breast/ovarian cancer. The calculation helps the 
person to find cancer early, and it will lower the risk of getting cancer. If the person is at risk of 
hereditary breast/ovarian cancer, it means that their close relatives have a 50% chance of having 
the same kind of mutation. 
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3 CHAPTER 3  
Different Models to Predict Breast Cancer 
Breast cancer risk assessment models help people in determining the risk. Medical 
practitioners use different models to assess the patient’s risk of developing breast cancer. All the 
breast cancer tools that are available now have many drawbacks, and the accuracies of these 
models are not perfect. These models assess the risk either as the probability of developing breast 
cancer or the probability of mutated genes that cause breast cancer. It is important to assess the 
risk very accurately to make the right steps in prevention strategies, which range from lifestyle 
changes to breast removal. It is required to develop an accurate model to assess individual risk. 
The accuracy of the models depends on many factors such as lifestyle, diet, and hereditary 
history. However, breast cancer is likely to occur even in the absence of these known factors. 
This chapter discusses different breast cancer risk assessment models and also compares 
different models. 
3.1 Gail Model 
The Gail model was developed by Dr.Mitchell Gail, a senior investigator in a biostatistics 
department. The risk factors considered for the Gail model were age at menarche, age at first live 
birth, number of previous biopsies, and the number of first-degree relatives with breast cancer. 
The model is based on the relative risks of various combinations of these factors taken from the 
Breast Cancer Detection Demonstration Project (BCDDP). The cases used for this model 
consisted of women with breast cancer between 1978 and 1980 at twenty-nine participating 
centers that involved 280,000 women aged 35 to 74 years. This model groups the patients into 
two categories based on their age. The relative risks connected with previous breast biopsies 
were smaller for women of age 50 and older than women younger than 50. The model, again, is 
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subdivided into three parts: (a) Estimating the relative risk for a subject with a given group of 
risk factors at a given age compared to a subject without the identified risk factors; (b) estimating 
the baseline age-specific breast cancer hazard rate, which is the rate for a woman without 
identified risk factors; and (c) projecting the long-term probability of developing breast cancer 
on the basis of a consideration of competing risks and the results on relative risk and baseline 
hazard (Gail et al., 1989). The model does not consider many medications such as oral 
contraceptives, thyroid supplements, rauwolfia preparations, and diazepam medications. Other 
habits such as cigarette smoking and methylxanthines have not been considered in the analysis. 
The other major factors that the Gail model does not include are body mass index, age at 
menopause, breast feeding, plasma estrogen, lobular carcinoma, breast density, second-degree 
relatives, third-degree relatives, ovarian cancer, and male breast cancer. This model is validated 
only for white women. The model has been tested in African American women and Asian and 
Pacific Islander women, and it underestimates the risk in African American women with 
previous breast biopsies. The data for African American women has been collected from the 
Women’s Contraceptive and Reproductive Experiences (CARE) and from SEER data. The data 
for Asian and Pacific Islander women has been collected from the Asian American Breast 
Cancer Study and SEER data. In order to improve the model, various studies have been 
conducting in Hispanic and other minor community women. 
3.2 Claus Model 
In the Claus model, the risk is calculated based on an autosomal dominant genetic model. 
The likelihood of this model is calculated from a joint analysis of mothers and sisters of the 
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white cases and controls. “The likelihood for the mother of a case was calculated conditional 
upon the age at onset of the case. For mothers of controls, the likelihood was calculated 
conditional upon the current age of the control. The likelihood for sisters of cases was calculated 
conditional upon the breast cancer status of the mother as well as the age at which the case was 
affected. The age at which a mother with breast cancer was affected, or, in the instance of an 
unaffected mother, her current age or age at death was also incorporated into the sister’s 
likelihood. For sisters of controls, the likelihood was calculated in the same fashion with the 
exception that current age on control was substituted for age at onset of case (Claus, Risch, & 
Thompson, 1993). 
The Claus model is widely used in research studies and clinical counseling. The data used 
in the Claus model is derived from the Cancer and Steroid Hormone Study. The case-control 
study is conducted by the Centers of Disease Control. There were 4,730 cases analyzed in the 
ages of 20 to 54 years, and 4,688 controls were matched to cases on the basis of both geographic 
regions and five-year categories of age (Claus, Risch, & Thompson, 1991). Family histories are 
obtained through interviews on different cases about breast cancer. The Claus model considered 
first- and second-degree relatives and age of onset of relatives. The model incorporates paternal 
and maternal family history and family history of ovarian cancer. The major limitations of the 
Claus model are that it may underestimate risk in hereditary families, may not be applicable to 
all combinations of affected relatives, and does not include risk factors other than family history. 
The model is best fit for individuals with no more than two first-degree relatives or second-
degree relatives with breast cancer. 
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 The Gail model and Clause model underestimate women from hereditary breast cancer 
families. This model is not a sole model for the families that have the following characteristics 
(NCI, 2015). 
 Three individuals with breast or ovarian cancer diagnosed before the age of 50 
 Women who have both breast and ovarian cancer 
 People who belong to Ashkenazi Jewish ancestry with at least one case of breast or 
ovarian cancer 
The Claus model assesses the probability of a woman developing breast cancer based on 
family history. However, it does not consider other risk factors such as bilateral breast cancer, 
male breast cancer, and ovarian cancer. The Claus model risk can be calculated as lifetime risk or 
an estimated risk over a ten-year period. The Claus model only considers first- or second-degree 
relatives, and it does not consider third-degree relatives. In addition, it does not include non-
hereditary risk factors. 
3.3 BRCAPRO Model 
The BRCAPRO model is statistical model associated with software (CancerGene v5.1) to 
measure the risk of germline deleterious mutation of BRCA1 and BRCA2 genes. This model was 
developed based on Mendelian approach, and it assumes autosomal dominant inheritance for 
BRCA1/BRCA2 genes. The model was originally developed in 1995 to 1999 by Parmigiani and 
colleagues, and it was later modified in 2007. The initial study sample consisted of 292 families 
that included at least one person tested for BRCA mutation. The family group included 104 
African American, 130 Hispanic, 37 Asian American, and 21 other minority families. The 
families have been identified mainly through two sources. The information for the first group is 
collected from the Breast Cancer Registry Family (BCFR). The second group was identified by 
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the Cancer Risk Clinic at the University of Chicago. The information about Ashkenazi families 
was not included initially and later had been added to the model. The major features that are 
included in the model are first-degree relatives, second-degree relatives, age of onset of breast 
cancer, bilateral breast cancer, ovarian cancer, and male breast cancer. This model considers both 
affected and unaffected relatives. This model gives an estimated result for either BRCA1 or 
BRCA2 mutation risk. The model computes the breast cancer risk based on the likelihood of 
BRCA1 or BRCA2 mutation risk. None of the non-hereditary factors such as alcohol intake, age 
at menarche, oral contraceptive pills use, and breast feeding are incorporated into this model. 
According to the study done by the Family History Clinic at the University Hospital of South 
Manchester, this model has the least accuracy in breast cancer risk assessment compared with the 
Gail, Claus, and Tyrer-Cuzick models (Amir et al., 2003). The model performed best in 
Hispanics (highest AUC- 0.83) and worst for African American families (AUC-0.68), and it 
provided intermediate result for other minority groups, mainly Asian-America and Native 
Americans (AUC-0.71) (Huo et al., 2009). This model appears to be worthy in predicting 
mutation risk in male patients. 
Advantages of BRCAPRO model (Petrucelli, Daly, & Fledman, 2010): 
 Estimates probability of mutation in BRCA1/BRCA2 
 Considers Ashkenazi Jewish Heritage 
 Frequently updated 
 Provides printout for pedigree analysis 
 Considers both affected and unaffected relatives 
Drawbacks of BRCAPRO model: 
 Analysis has been done based on high-penetrance families 
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 Considers only first- and second-degree relatives 
 Needs CancerGene software and data entry for each family 
The BRCAPRO model performs well in pretest prediction of BRCA mutation, especially 
in minority communities and Hispanic families, maybe because they are genetically closer than 
other white populations. 
3.4 Cuzick-Tyrer Model 
The Cuzick-Tyrer model was designed to predict ten-year risk of breast cancer 
development using genetic and non-genetic risk factors. The Cuzick-Tyrer model is the most 
reliable and accurate model for prediction of breast cancer. The Cuzick-Tyrer statistical model 
calculates the risk of breast cancer by considering many factors such as family history, age at 
menarche, parity, age at menopause, atypical hyperplasia, age at first childbirth, height, lobular 
carcinoma in situ, and body mass index. The program assumes that there are other genes that 
influence breast cancer other than the BRCA genes. The patient’s family history is used to 
estimate the probability of carrying a faulty gene that affects the possibility of developing breast 
cancer. The data for the model has been collected from the International Breast Intervention 
Study and other epidemiological data. According to different studies, the Cuzick-Tyrer model is 
the best model to assess breast cancer risk, as it is integrated with family history, estrogen 
exposure, and benign breast diseases. The risk factors of the individual are collected through 
questionnaires and through a review of medical records. A separate analysis has been done for 
women with atypical hyperplasia, as this disease has a high risk of breast cancer. Among 9,376 
patients, 331 women were identified with atypical hyperplasia (Boughey et al., 2010). This 
model advises genetic counselling when the risk level of BRCA1/BRCA2 is 10% or higher. The 
IBIS tool (http://www.ems-trials.org/riskevaluator/) is the software tool that has been developed 
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based on the Cuzick-Tyrer model. The tool does not include risk factors such as lifestyle, breast 
density, and third-degree relatives. The key benefit over the Claus model and the BRCAPRO 
model is that the Cuzick-Tyrer model permits the presence of multiple genes of different 
penetrance levels. The algorithm for this model produces information of BRCA1/2 along with 
lower penetrance of BRCAX. The model incorporated women who have a single first-degree 
relative affected by breast cancer. This model also considers ovarian cancer history, as ovarian 
cancer has a significant effect on breast cancer. The Cuzick-Tyrer model also accurately predicts 
risk in women whose menarche appeared after the age of 12 years. Even though the model is 
more powerful than other models at the current time, it is less available to primary care providers 
than other models. 
3.5 BOADICEA Model 
The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm 
(BOADICEA) is a statistical model used to compute the risk of hereditary breast and ovarian 
cancer. This model uses the BRCA1/BRCA2 mutation probabilities to calculate the risk of 
breast/ovarian cancer. The model was developed based on 2,785 families and has been validated 
in a large series of families from UK genetics clinics. There are some limitations related to the 
first version of BOADICEA. “The model assumed that a fixed set of calendar period incidences 
applied to all cohorts, when breast cancer incidences have been increasing over time. As part of 
the model-fitting process, we also estimated the BRCA1 and BRCA2 breast and ovarian cancer 
risks, but these were based on a relatively small number of mutation-carrying families and were 
therefore imprecise” (Antoniou et al., 2008). To calculate the risk, BOADICEA considers the 
family history of breast, ovarian, prostate, and pancreatic cancer. A new version of BOADICEA 
has included specific incidents of these cancers from different countries. This model uses the 
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Mendalian approach to analyze the pedigree of the family history (Lee et al., 2014). The model 
does not include non-hereditary factors such as age at menopause, alcohol intake, contraceptive 
pill use, or body mass index. MENDEL is a breast cancer prediction software program that has 
been developed based on BOADICEA, and it is useful for families of an arbitrary size and 
structure. The model was developed based on families which are mainly from the UK, and it also 
included a few families from Sweden. The model was created for invasive breast cancer and is 
less accurate for ductal cancer in situ (DCIS).  
This model groups people who were born in a particular period, and it analyzes the breast 
and ovarian cancer risk for each person developing cancer during a particular time. The 
estimated population frequency for the BRCA1 mutation was 0.06% and for the BRCA2 
mutation was 0.10% (Antoniou et al., 2008). The model calculates breast cancer risks in BRCA1 
and BRCA2 carriers on a birth cohort effect, and the risk increases in more recent birth cohorts. 
For example, women who born in 1920–1929 show an average cumulative breast cancer risk of 
50%, and it is 58% for women born after 1950. 
3.6 Comparison of Different Models 
The main drawbacks of the Gail model is that it does not consider second- or third-degree 
relatives to assess the risk and mainly focusing on non-genetic factors. In addition, this model 
does not count age of onset of breast cancer, bilateral breast cancer, ovarian cancer, and male 
breast cancer, and it does not calculate the risk of getting breast cancer in the subsequent time. 
The Gail model measures risk based on patient age, age at menarche, number of prior breast 
biopsies, age at first live birth, and number of first-degree relatives affected by breast cancer 
(Evans & Howell, 2007). The tool is designed for health professional such as doctors and nurses. 
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Therefore, the terms and explanations might not be easy to understand for people who have less 
knowledge about breast cancer. 
Table 2  
Comparison of Different Models 
 
Factors considered 
 
Gail model Claus 
model 
BRCAPRO 
model 
Cuzick–
Tyrer model 
BOADICEA 
model 
Age (20–70 years) Yes Yes Yes Yes Yes 
Body mass index No No No Yes No 
Alcohol intake (0–4 
units) daily 
No No No No No 
Age at menarche Yes No No Yes No 
Age at first live birth Yes No No Yes No 
Age at menopause No No No Yes No 
Hormone 
replacement therapy  
No No No Yes No 
oral contraceptive 
pill use 
No No No No No 
Breast feeding No No No No No 
Plasma estrogen No No No No No 
Breast biopsies Yes No No Yes No 
Atypical ductal 
hyperplasia 
Yes No No Yes No 
Lobular carcinoma 
in situ 
No No No Yes No 
Breast density No No No No No 
First-degree relatives Yes Yes Yes Yes Yes 
Second-degree 
relatives 
No Yes Yes Yes Yes 
Third-degree 
relatives 
No No No No Yes 
Age of onset of 
breast cancer 
No Yes Yes Yes Yes 
Bilateral breast 
cancer 
No No Yes Yes Yes 
Ovarian cancer No No Yes Yes Yes 
Male breast cancer No No Yes No Yes 
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The Cuzick-Tyrer model and the Claus model are developed based on family history that 
includes first- and second-degree relatives. These tools are not available to the public and are 
generally made for medical professionals (R. Ellsworth, Decewicz, Shriver, & L. Ellsworth, 
2010). Neither of these tools considers male breast cancer history. The Claus model is not linked 
to important family history factors such as bilateral cancer and ovarian cancer. The Claus and 
BRCAPRO models were developed fifteen to twenty-five years ago, and worldwide breast 
cancer incidence has increased by more than 20% since 2008. Therefore, the risk estimates based 
on lower-risk populations underestimate the current risk. The BOADICEA model is only 
predicting the risk of BRCA1/BRCA2 mutation (Ellsworth et al., 2010). It does not count other 
potential genes such as PTEN or Tp53 for the studies.  
 The Claus and Gail models are mainly used in research studies and clinical risk 
assessments. The discriminatory accuracy and best fit of the Gail, Claus, BRCAPRO, and 
Cuzick-Tyrer models have been calculated taking data from 1,933 women attending the Family 
History and Screening Program in the UK. These models are implemented to estimate the breast 
cancer risk assessment in women over a follow-up of five years. The ratio of the expected to 
observed cases of breast cancers was 0.48 for the Gail model, 0.56 for the Claus model, 0.49 for 
the BRCAPRO model, and 0.81 for the Cuzick-Tyrer model. The accuracy for each model has 
been developed separately, and the AUC (Area Under the Curve) for the Gail model was 0.735, 
for the Claus model was 0.716, for the BRCAPRO was 0.737, and for the Cuzick-Tyrer model 
was 0.762 (Evans & Howell, 2007). The Cuzick-Tyrer model was the most consistent and 
accurate model. The Claus, Gail, and BRCAPRO models significantly underestimated the risk, 
especially with people who had a single first-degree relative with breast cancer. The Claus model 
gives better accuracy if it is manually adjusted for the risk factors. The Cuzick-Tyrer and manual 
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models were accurate in this case. However, all models accurately predicted the risk in people 
with multiple relatives diagnosed with breast cancer. The Gail model was less accurate in 
predicting risk with a single first-degree relative, as it does not count the age at onset of the 
cancer. The BRCAPRO and Cuzick-Tyrer models were the only accurate models which have 
approximately similar values to the manual model in perdition of risk with a family history of 
ovarian cancer. This is the only model which considered ovarian cancer history to predict the 
breast cancer risk. The Gail, Claus, and BRCAPRO models underestimated the risk in women 
regarding age of first birth, and these models underestimate the risk factor in women whose 
menarche appeared after the age of 12 years (Evans & Howell, 2007). The BOADICEA model 
has almost the same approximate prediction value as the Claus and BRCAPRO models. The 
BOADICEA model is a polygenetic model, and it examines the risk of BRCA1/BRCA2 
mutation along with breast cancer risk. The BRCAPRO and BOADICEA models have high 
diagnostic accuracy in predicting the mutation risk of BRCA1/BRCA2, and the BOADICEA 
model has been further modified with tumor markers (ER), progesterone receptors (PR), and 
human epidermal growth factor receptor 2 (HER2) (Biswas et al., 2012; Tai, Chen, Parmigiani, 
& Klein, 2008). The limitations of the models are the strength of the research data, the 
population used, and the overestimation in gene harboring (Aiello-Laws, 2011). 
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4 CHAPTER 4  
Analyzing Hereditary Information in Predicting Breast Cancer 
There are some particular features that may predict the possibility of a hereditary cancer 
syndrome associated with a single gene mutation. The main features of hereditary cancer 
syndromes are a family member with more than one cancer, patterns of autosomal dominant 
transmission, bilateral cancer, rare cancer, precursor lesions, male breast cancer, ovarian cancer, 
and breast cancer. The information collected can be used to determine whether the cancer in an 
individual or family is associated with an inherited predisposition and to establish the most likely 
differential diagnosis (Aiello-Laws, 2011).  
The presence of mutated breast cancer genes is detectable in current or future generations 
based on the information gathered from family history. Family health history plays a major role 
in determining the risk factors, as it gives a link to hereditary, environmental, cultural, and 
behavioral factors of the entire family (Yoon et al., 2003). The risk factors involved in breast 
cancers are age, gender, genetic factors, family history, race/ethnicity, and habits. Breast cancer 
occurs more often in females than in males because of the female hormones like estrogen and 
progesterone, which help cancer cell growth (American Cancer Society, 2014). This section 
analyzes the different genes that are considered for the prediction of breast cancer. The risk of 
developing breast cancer increases with age. Many factors can be found in a family history that 
is suggestive of BRCA pathogenic variant. The clues include, multiple individuals on one side of 
the family with breast or ovarian cancer, a young average age of diagnosis, male breast cancer, 
associated cancer, individuals with more than one primary cancer, including bilateral breast 
cancer, Ashkenazi Jewish Ancestry (Murray & Davies, 2013). 
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4.1 Discussion on Gene Affecting Breast Cancer 
 
Figure 2. Cell, chromosomes and DNA. 
Proteins are large molecule that plays important role in our body. Proteins help the cell to 
work properly. The proteins are made up with amino acids. There are different kinds of amino 
acid that together make a protein molecule. The particular sequencing of amino acids make a 
specific function to each protein. Genes are made up with these different functional molecules 
(protein) and also it is a part of DNA. A gene is a segment of DNA that is inherited from parents 
to children, and it determines the traits of the offspring. Every gene has different functions, such 
as embryo development, cell growth, personality, eye color, or metabolism. DNA is a molecule 
that stores the genetic information of any living organisms.  
DNA is a molecule that contains nucleotides which are the building blocks of DNA. A 
nucleotide is made up of a phosphate group, a sugar group and a nitrogen base. RNA or 
34 
 
 
ribonucleic acid is another type of nucleic acid, and it transfers genetic information from DNA to 
a body cell.  
Nucleotides are paired together and form a double helix structure. Each side of the double 
helix is made up of the phosphate and sugar molecules and the nitrogen bases connect each side. 
The chains are composed of four different nucleotides, namely Adenine, Guanine, Cytosine and 
Thymine (Williams, 1997; National Library of Medicine [NLM], 2015). The order of these 
chemical letters determines DNA's information or genetic information. The nitrogen bases are 
always found in pairs; adenine pairs with thymine, and guanine pairs with cytosine. 
Chromosomes are a spiral shaped form of DNA. 
The DNA sequence can be mutated in many ways. The different kind of mutation 
include, missense mutation, nonsense mutation, insertion, deletion, duplication and frameshift 
mutation. Missense mutation occurs when a DNA base pair sequence change and that substitute 
one amino acid for another. Nonsense mutation also occurs when the DNA base pair become 
damaged. In nonsense mutation mutated DNA signals the cell to stop building protein. In 
insertion mutation, DNA sequencing get altered by another piece of DNA. As a result the gene 
may not function properly. Deletion mutation changes the DNA sequencing by removing a piece 
of the DNA sequence. The deleted DNA cause malfunctions in protein synthesis. In duplication a 
section of DNA is repeated accidently and thus makes the malfunction of the protein. Frameshift 
mutation occurs when any changes occur in reading frame of DNA. A reading frame include 
three bases and each base corresponds to one amino acid. When the frameshift mutation occurs it 
shift these bases and thus amino acid get base that not supposed to have. As a result the protein 
synthesis may go wrong. A short DNA sequence called Nucleotides are repeating many times in 
35 
 
 
a DNA sequence row. Trinucleotide repeat 3 times and tetra nucleotide repeat four times. If this 
chain is repeated unwanted or abnormally makes the protein malfunction.  
DNA sequencing can be damaged by many mutagens such as oxidizing agents or 
alkylating agents and by radiation like X-rays, UV rays, and electromagnetic radiation. Any 
changes in the DNA sequence of the gene can cause genetic disease. Cancers can be hereditary, 
and they pass the gene mutations to the next generations through a specific inheritance pattern. 
Mutated genes such as BRCA1, BRCA2, Tp53, and PTEN confer high lifetime risk of breast 
cancers (Lalloo & Evans, 2012). There are other genes such as PALB1, BRIP and LKB1 behind 
breast cancer, which contribute moderate risk. However, BRCA1, BRCA2, TP53, and PTEN are 
the most considered genes for clinical studies.  
 Medical information about other factors that cause cancers such as hormone level, 
gender, lifestyle, diet, habits, pollution, and physical activity helps to predict non-hereditary 
cancers in the current generation. We estimate the analytical validity of the information that is 
gathered from the information by comparing it with the results that have been already determined 
by scientists through experiments. 
4.1.1 BRCA1 and BRCA2. Hereditary Breast or Ovarian Cancer Syndrome (HBOC) 
hereditary genetic condition, and the genes associated with this syndrome are BRCA1 and 
BRCA2 (BReast CAcer ). Most of the breast and ovarian cancers are not hereditary. Both the 
BRCA1 and BRCA2 genes are responsible for protein involvement in tumor suppression. 
BRCA1 is located on chromosome 17 and is involved in the repair and regulation of DNA 
damage. The BRCA2 gene is located on chromosome 13 and is involved in DNA break and 
repairs (Murray & Davies, 2013). Both genes exhibit high penetrance, ranging from 41% to 90%, 
with increased risk of other related cancers such as ovarian cancer, epithelial cancer, pancreatic 
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cancer, and prostate cancer. Male carries of the BRCA gene confer high risk of breast cancer, 
especially if the gene is BRCA2. The risk of breast cancer increases if the person has close blood 
relatives who have breast cancer. The risk increases as the number of affected relatives increase 
and also varies in accordance with people’s race and ethnicity. A woman who is an Ashkenazi 
descendant has more risk of developing breast cancer if she is a carrier of the mutated genes 
BRCA1 and BRCA2.  
 It has been calculated that 90% of the early onset breast/ovarian cancer in families is 
triggered by BRCA1/BRCA2 mutations (Murray & Davies, 2013). Therefore, the risk of 
developing breast/ovarian cancer is relatively high if the individual has a personal or family 
history of both cancers. The risk level of developing breast or ovarian cancers due to the 
mutation of BRCA1/BRCA2 genes may vary even within families with same mutations 
(Abeliovich et al., 1997; Pagon et al., 2013). The estimation can vary from a 41% to 90% 
lifetime risk of breast cancer (Antoniou et al., 2003; Chen & Parmigiani, 2007; King, Marks, & 
Mandell, 2003). A published study shows that the calculated risk of BRCA1 mutation indicates 
that risk of developing breast and ovarian cancer is 57% and 40%, respectively. In the same 
scenario with BRCA2, the risk is 49% and 18%, respectively (Chen & Parmigiani, 2007).  
 Several studies shows that 9% to 21% of BRCA1 mutation is more likely to be linked 
with triple negative breast cancer (Atchley et al., 2008; Young et al., 2009). In addition to that, 
BRCA1 mutation appears at early ages among people who have triple negative breast cancer 
when compared with non-carriers (Gonzalez-Angulo, 2011; Lee, 2011). For a person with triple-
negative breast cancer with a family history of breast/ovarian cancer, the risk of BRCA1 
mutation was 48% (Fostira et al., 2012). Among Ashkenazi Jewish families, people who have 
personal histories of triple-negative breast cancer had identified with 11% of BRCA1 mutations. 
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Different studies show that triple-negative breast cancer is also associated with BRCA2 
mutations (Comen et al., 2011). The risk of BRCA2 mutation related to personal history of 
triple-negative breast cancer ranges from 4% to 17% (Comen et al., 2011). Germline mutations 
of BRCA1 and BRCA2 mutations associated with prostate cancer, especially BRCA2 mutation, 
are linked with two to six times’ higher risk (Agalliu, Gern, Leanza, & Burk, 2009; Kirchoff, 
2004). Patients with prostate cancer due to BRCA2 mutations show decreased survival compared 
with BRCA1 mutations (Thorne, 2011). BRCA2 mutation is also linked with a higher risk of 
pancreatic and melanoma cancer than BRCA1 mutation. In addition, BRCA2 mutations have 
more response with chemotherapy treatment when compared with BRCA1 or non-carrier cases. 
Germline mutations of BRCA1 and BRCA2 are accountable for 5% to 10% of epithelial ovarian 
cancer (Jazaeri, 2003). The history of ovarian cancer with BRCA1/BRCA2 mutations is more 
likely linked to adenocarcinoma. Male carries of BRCA2 mutation also have a high risk of 
cancer susceptibility. The cumulative lifetime risk for breast cancer among a male who carries 
BRCA2 mutation is 7% to 8% (Evans et al., 2010). However, men without any mutation have a 
0.1% lifetime risk. The NCCN panel recommends that individuals from a family with known 
BRCA1/BRCA2 mutation should be considered at risk (Evans et al., 2010). 
4.1.2 PTEN. PTEN is a tumor suppressor gene, and it regulates normal cell process, 
including growth, adhesion, migration, invasion, and apoptosis (Yamada & Araki, 2001). 
Approximately 80% of cancer patients carry a mutated PTEN gene if they meet NCCN clinical 
criteria for Cowden syndrome. Women identified with Cowden syndrome have high risk of 
benign fibrocystic breast diseases, and their lifetime risk of breast cancer has been estimated at 
25% to 50% with an average age of 38 to 46 years at diagnosis. 
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 Cowden syndrome is considered as very rare disease, and it is underestimated because of 
the difficulties associated with clinical diagnosis. Cowden syndrome is associated with the tumor 
suppressor gene PTEN, and it exhibits the autosomal dominant inheritance pattern (Pilarski, 
2009). PTEN gene mutation is also related with PTEN Hamartoma tumor syndromes (PHTS), 
Bannayan Riley Ruvalcaba syndrome (BRRS), Proteus syndrome, Proteus-like syndromes, 
Lhemitte-Duclos disease, and autism spectrum diseases (Eng, 2014; Pilarski, 2009; Pilarski, 
Stephens, Noss, Fisher, & Prior, 2011). PTEN mutation is associated with breast cancer, thyroid 
cancer, endometrial cancer, colorectal cancer, renal cancer, and melanoma. The calculated 
lifetime risk of cancer is 85% for breast, 34% for renal, 35% for thyroid, 28% for endometrial, 
9% for colorectal, and 6% for melanoma (Tan et al., 2012). Women with PHTS have higher risk 
than men with PHTS. Women diagnosed with Cowden syndrome have high risk of developing 
fibrocystic breast diseases which has breast cancer risk ranges from 25% to 50%. There are only 
two cases reported in men with Cowden syndrome (Pilarski, 2009). Approximately 70% people 
with the PTEN gene mutation are linked with multi-nodular goiter, follicular adenomas, 
adenomatous nodules, and follicular adenomas. Classic features of Cowden syndrome include 
mucocutaneous papillomatous papules, trichilemmomas, and palmoplantar keratosis. The study 
shows that about 40% people with Cowden syndrome have gastrointestinal polyps 
(hamartomatous, ganglioneuromas). The people who meet the criteria have a risk of carrying the 
PTEN gene of 85% or higher (Gonzalez et al, 2009; Schaffer, Kamino, Witkiewicz, McNiff, & 
Orlow, 2006). Early onset colorectal cancer is found in person with PTEN mutations. People 
with BRRS variant have approximately a 60% risk of PTEN mutation. The people who meet 
Cowden syndrome criteria will have about an 80% chance of carrying faulty a PTEN gene 
(Gonzalez et al, 2009). While calculating Cowden syndrome risk, there are some major and 
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minor features that should be considered. The major features include the personal history of 
breast cancer, follicular thyroid cancer, endometrial cancer, macrocephaly, multiple 
gastrointestinal hamartomas or ganglioneuromas, and certain mucocutaneous lesions (Eng, 2000; 
Pilarski et al., 2009). A person who meets two or more major criteria with one macrocephaly 
meets the criteria for Cowden syndrome. An individual who meets three or more major criteria is 
at risk of PTEN mutation. A person with one major criterion and three minor criteria is also 
considered a person at risk. The minor criteria include colon cancer, autism spectrum disorder, 
esophageal glycogenic acanthosis, mental retardation, lipomas, thyroid cancer, gastrointestinal 
hamartoma, and testicular lipomatosis (Eng, 2000; Pilarski et al., 2009). An individual who 
meets four or more minor criteria can be considered at risk of Cowden syndrome. A first-degree 
relative with one or more major criteria and two or minor criteria along with a relative diagnosed 
with Cowden syndrome meets the threshold. 
4.1.3 Tp53. Tumor protein Tp53 is another gene that has high penetration to cause breast 
cancer. Breast cancer is common in women with Li-Fraumeni Syndrome (LFS). There are 
different tumors associated with LFS syndrome (Gonzalez et al., 2009). The LFS tumor spectrum 
includes soft-tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumors, 
adrenocortical carcinoma (ACC), leukemia, and lung Bronchoalveolar cancer (LFS tumor 
spectrum). The lifetime risk of breast cancer in a woman with the Tp53 gene is 49% by the age 
of 60. According to the clinical study, a patient with invasive breast cancer and a family history 
of no core cancer has a 0% chance of having the p53 mutation. However, a person with breast 
cancer under the age of 30 and with a family history of one or more core cancers in first- or 
second-degree relative has a 100% chance of having the p53 mutation. Patients younger than 30 
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with unilateral breast cancer and no cancer in first- or second-degree relative have a 7% chance 
having the p53 mutation (Gonzalez et al., 2009).  
Li-Fraumeni syndrome is a rare hereditary diseases associated with germline mutations of 
Tp53. Only 1% of hereditary breast cancers are related with germline mutation of Tp53. It is 
located on chromosome 17 and it is known as “guardian of genome.” Tp53 gene plays an 
important role in cell cycle and apoptosis. An individual who meet Classic Li-Fraumeni 
syndrome criteria has a 50% - 70% risk of Tp53 gene mutation. LFS is a high penetrant cancer 
syndrome, and it is associated with soft-tissue sarcomas, osteosarcomas, acute leukemia, colon 
cancer, premenopausal breast cancer, adrenal cortex cancer, and brain tumors. Sarcoma, breast 
cancer, adrenocortical tumors, and brain tumors are known as core cancers of LFS syndrome, as 
they are mostly related to Tp53 mutation. Studies show that HER-positive breast tumors are 
highly associated with Tp53 mutation. Individuals with soft-tissue sarcomas, brain tumors, or 
adrenocortical carcinomas at early ages will have a high lifetime risk of developing multiple 
primary cancers. When compared with males, female breast cancer is more often related to LFS 
syndrome. NCCN guidelines give different criteria to identify LFS syndrome. Classic LFS 
syndrome criteria include individuals with known Tp53 mutation, individuals diagnosed with 
sarcoma before the age of 45 years, a first-degree relative diagnosed with cancer before the age 
of 45, and an additional first- or second-degree relative with the same cancer diagnosed at the 
age of 45 or younger or with sarcoma at any age. Classic LFS has high prediction value (56%) 
and specificity. Some other works have been done by different groups to make the LFS criteria 
more accurate and predictive. Birch and colleagues have added more cancers to the LFS criteria. 
Chompret and his colleagues added many criteria, including patients with multiple tumors, at 
least two core tumor types diagnosed before the age of 36, and patients with adrenocortical 
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carcinoma diagnosed at any age. The Chompret criteria has 20% to 35% prediction values, and 
when it is added to classic LFS criteria, it improves the prediction value to 95%. Women who 
identify breast cancer before the age 35 with or without family history of core cancers of LFS 
syndrome can be considered at risk of Tp53 mutation. Studies show that women with breast 
cancer before the age of 35 have a 3% to 8% risk of Tp53 mutation. A member from a family 
with known deleterious Tp53 mutation is always at risk even without any symptoms of cancer.  
4.2 Inheritance Patterns of BRCA1, BRCA2, Tp53 and PTEN Genes 
Humans have twenty-three pairs of chromosomes. The first twenty-two are called 
AUTOSOMES and the twenty-third pair is the SEX CHROMOSOMES (the pair of 
chromosomes that determines the gender of the offspring) (NLM, 2015). Mutated genes are 
inherited from biological parents in specific ways. Autosomal dominant inheritance is one of the 
basic patterns of inheritance. Autosomal dominant inheritance means that the gene carrying a 
mutation is located on one of the autosomes (chromosome pairs 1 through 22). This means that 
males and females are equally likely to inherit the mutation. In autosomal dominant mutation, 
just one of the two copies of a particular gene is enough for a person to have a trait, such as an 
increased risk of developing cancer (Chapman, 2007). Autosomal recessive inheritance means 
that the gene carrying the mutation is located on one of the autosomes (chromosome pairs 1 
through 22). In autosomal recessive inheritance, both copies of the gene must have a mutation in 
order to make a person have the trait. A person who has only one recessive gene mutation is said 
to be a "carrier" of the trait or disease, but he/she does not have any health problems from 
carrying this one mutated gene (Williams, 1997). 
 Genetic conditions are caused by mutations in single genes and can be inherited in 
different ways. Single gene inheritance is called Mendelian inheritance, and there are four 
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different types of Mendelian inheritance patterns: 1) autosomal dominant, 2) autosomal 
recessive, 3) X-linked recessive, and 4) X-linked dominant (National Library of Medicine, 
2015).  
4.2.1 Autosomal dominant inheritance. Autosomal dominant inheritance means that the 
gene carrying a mutation is located on one of the autosomes (chromosome pairs 1 through 22). In 
autosomal dominant inheritance, only one copy of the faulty gene is sufficient to make the 
individual at the risk of the disease. Autosomal dominant disorders are likely to occur in each 
generation of an affected family.  
 When a parent has a dominant gene mutation, there is a 50% chance that any child he/she 
has will also inherit the mutation. There are four possible combinations in the children. Two of 
the four, or 50%, have inherited the mutation. The other 50% have not inherited the mutation. 
These four combinations are possible every time a pregnancy occurs between these two 
individuals. The gender of the children (whether they are sons or daughters) does not matter. The 
chance is fifty-fifty for each pregnancy. BRCA1, BRCA2, PTEN and Tp53 genes exhibit the 
autosomal dominant inheritance pattern. 
4.2.2 Autosomal recessive inheritance. In each cell, two mutated copies of the gene 
should be present to make the person at risk of disease. "Recessive" means that both copies of 
the faulty gene should be inherited to make the person susceptible. A person who has only one 
recessive gene mutation is said to be a "carrier" for the trait or disease, but he/she does not have 
any health problems from carrying this one mutation. Most people do not know they carry a 
recessive gene mutation for a disease until they have a child with the disease. Once parents have 
had a child with a recessive disease, there is a one out of four, or 25%, chance with each 
subsequent pregnancy for another child to be born with the same disorder. This means that there 
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is a three out of four, or 75%, chance for another child to not have the disease (National Library 
of Medicine, 2015). 
4.2.3 X-linked dominant inheritance. X-linked dominant conditions are affected by 
mutations in genes on the X chromosome. Females are more commonly affected than males, and 
passing on an X-linked dominant disorder has a different outcome for men and women. Families 
with X-linked dominant diseases have frequently affected both males and females in each 
generation. In X-linked inheritance, the father cannot pass the faulty gene to their sons (NLM, 
2015).  
4.2.4 X-linked recessive inheritance. These disorders are due to the mutations in genes 
on the X chromosome. Males are more often affected than females. X-linked recessive disorders 
are frequently found in males but rarely affect females.  
 The next section will explain how the inheritance pattern is used for this software tool. 
The BRCA1/BRCA2, PTEN, and Tp53 genes exhibit autosomal dominant inheritance pattern. 
The mutated gene can be inherited by the next generation in different ways, and it depends on the 
gene that is involved with the disease. Consider a mother who is the carrier of the abnormal gene 
“a” and the father who is carrying the normal gene “A”, as shown in Figure 3. In hereditary 
breast cancer, the gene passes to the next generation through an autosomal dominant inheritance 
pattern. Every child inherits two copies from their parents, one from their mother and one from 
the father (National Center for Biotechnology Information [NCBI], 2009; HHS, 2013). When a 
parent has a dominant gene mutation, there is a 50% chance that any child from each pregnancy 
will inherit the mutation. The BRCA1, BRCA2, Tp53, and PTEN genes exhibit the autosomal 
inheritance pattern.  
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Figure 3. Autosomal dominant inheritance pattern. 
 A person with autosomal dominant inherited diseases will have four different possibilities 
with each pregnancy. Two out of the four, or 50%, can inherit the mutated genes (aA, aA). The 
other 50% do not inherit the mutated genes (AA, AA). These four combinations are possible 
every time a pregnancy occurs. The gender of the children does not matter. 
4.3 How the Traits are Passing Down to the Generations? 
Most cancers are non-hereditary, and hereditary cancers are commonly caused by genetic 
defect. There are two main categories of mutation based on the type of cell that the genetic 
change occurs in. Mutations that are passed from parents through the egg or sperm are known are 
inherited mutations. Somatic mutations can happen in the lifetime of any person. They are not 
inherited from their parents and it will not pass to the next generations.  
 Two main types of genes that play a role in cancer are proto-oncogenes and tumor 
suppressor genes. Tumor suppressor genes control cell division and repair DNA mistakes. When 
tumor suppressor genes don't work properly, cells can grow out of control, which can lead to 
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cancer. Many different tumor suppressor genes have been found, including TP53 (p53), BRCA1, 
BRCA2, APC, and RB1. Proto-oncogenes speed up the cell division and in any mutation can 
cause uncontrollable growth of the cells. The mutated proto-oncogenes are called oncogenes. 
When this happens, the cells grow out of control, which can lead to cancer. 
 The mutated gene can be inherited to the next generation in different ways, and it 
depends on the gene that involved with the disease. Genes are found in pairs. Each parent 
contributes one copy of the gene to their child. These gene copies can be inherited from parents 
in different ways, which are called inheritance patterns.  
 For example, some of the hereditary disease shows autosomal recessive inheritance. That 
means two copies of the abnormal genes must be present in order for the disease or trait to 
develop. Most people do not know that they carry a recessive gene mutation for a disease until 
they have a child with the disease. Once the mother has conceived a child, there is 25% chance 
of getting a normal child without the mutated gene. There will be a 25% of chance a child born 
with the disease. This means that there is a two out of four, or 50%, chance of getting a child 
who carries the mutated gene and may not show any symptoms of the disease in his or her 
lifetime.  
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5 CHAPTER 5  
Prediction of Hereditary Breast Cancer 
The capabilities of today’s digital world make innovative progress in health care. Doctors 
take advantage of fully functional and exchangeable electronic health records to provide better 
treatment and care. Health records that are stored in an electronic format deliver high accuracy in 
diagnoses and health outcomes. Nowadays, people use the Internet and medical websites to get 
more health information about diseases. Cancer is predictable in current or future generations 
based on the information gathered from family history tools and genetic and medical 
information. Collecting data from close relatives may be sufficient in determining the risk. 
However, risk prediction will be limited if the families are small. Predictions of diseases like 
breast, ovarian, colorectal, and prostate cancers have high degrees of accuracy if they have been 
developed based on family history (Santaguida et al., 2007). Identifying repeated diseases and 
associated genes would help to forecast the disease in the future generation (offspring). As we 
are concentrating on breast cancer, the next section will explain how a family history will be 
useful in predicting breast cancer in any individual or their next offspring. The aim of this 
research is to develop a software tool to predict hereditary breast cancer. We combine the 
medical, genetic, and family health history reports to create the program.  
5.1 Flowchart to Predict the Hereditary Breast Cancer Risk 
There are different models and software programs that have been developed to predict the 
risk of breast cancer (Evans & Howell, 2007). However, these tools do not consider other genes 
such as TP53 and PTEN that contribute a high risk for breast cancer. In this computer program, 
we have combined BRCA1/BRCA2, TP53, and PTEN gene risks. We are using National 
Comprehensive Cancer Network guidelines to predict BRCA1, BRCA2, TP53, and PTEN 
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mutation risk. According NCCN members Daly et al, the guidelines for breast and ovarian 
cancer are focusing on assessment of mutations in the genes BRCA1, BRCA2, TP53, and PTEN, 
and recommended approaches to genetic testing and management strategies.  
The National Comprehensive Cancer Network (NCCN) is an association of twenty-five 
global leading cancer centers. The association develops guidelines for most cancers and is 
updated by forty-seven individual panels, including over 950 clinicians and oncology researchers 
from the twenty-five institutions that are members of the NCCN. The panel members include 
clinicians and researchers, and they have several academic disciplines. According to NCCN 
guidelines (Daly et al., 2014), “It should be emphasized that these guidelines were not developed 
as a substitute for professional genetic counseling. Rather they are intended to serve as a resource 
for healthcare providers to identify individuals who may benefit from cancer risk assessment and 
genetic counselling, to provide genetic counselors with an updated tool for the assessment of 
individual breast cancer and ovarian cancer risk and to guide decisions related to genetic testing, 
and to facilitate a multidisciplinary approach in the management of individuals at increased risk 
of hereditary breast and ovarian cancer. Although cancers other than breast and ovarian cancers 
are associated with these hereditary syndromes, the main focus of this NCCN Guidelines is on 
the management of breast and ovarian cancer risk in these individuals” (Daly et al., 2014). 
Moreover, new guidelines go through annual reviews, and it will be circulated among 
multidisciplinary researchers for comments at each NCCN branches. 
The flowcharts have been developed based on NCCN guidelines, and the analysis has 
been divided into three sessions: 1) Hereditary breast/ovarian cancer syndrome analysis 2) Li-
Fraumeni syndrome analysis and 3) Cowden syndrome analysis. These three syndromes are 
related to germline mutation of BRCA1/BRCA2, TP53, and PTEN genes that have high impact 
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on hereditary breast cancer diagnoses. The below figures give details about the logical flow of 
the program. In this program, we have used the latest version of the guidelines (Daly et al., 
2014).  
5.1.1 Checking BRCA1/BRCA2 mutation. 
 
Figure 4. BRCA1/BRCA2 personal history analysis. 
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Figure 5. BRCA1/BRCA2 personal history analysis (cont.). 
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Figure 6. BRCA1/BRCA2 family history analysis. 
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Figure 7. BRCA1/BRCA2 family history analysis (cont.). 
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The figure 4 and figure 5 shows the procedures of personal history analysis of BRCA1 or 
BRCA2 mutation risk. After collecting the information about already known or diagnosed 
mutation of BRCA1/BRCA2 gene, it checks the personal history of breast cancer. 
 In order to check the personal history of breast cancer, the flowchart has been divided 
into four groups based on different age category. The risk criteria will be met if the person is 
under the age category ‘a’ (age <=45), and there are no additional criteria needed to satisfy the 
‘at risk’ condition. The criteria will be met, if the person is under or at the age of 50, and if 
she/he has any additional primary breast cancer or more than one close blood relatives with 
breast cancer. The person will be at risk if she/or he has an unknown family history. If the age 
category is 60 or under, the result will be stored if the person is identified with triple negative 
breast cancer. For ‘at any age’ category, and the criteria will be met if more than one close blood 
relatives with breast cancer at 50 or younger age, or more than two close blood relatives with 
breast cancer at any age, or more than one close blood relatives with male breast cancer, or more 
than close blood relatives with pancreatic or prostate cancer. The result will be stored, if the 
person belongs to Ashkenazi Jewish Ancestry, and if the person has a personal history or family 
history of breast or prostate cancer.  
After that, the result will be stored if the person has an epithelial ovarian cancer history. 
In addition, the flowchart checks the personal history of male breast cancer. Next, it checks the 
personal history of pancreatic or prostate cancer.  
After checking the personal history of pancreatic or prostate cancer history, the family 
history of breast, ovarian, pancreatic and prostate cancers will be checked. If there are more than 
two relatives from the same side of the family is affected with any of these cancers, the result 
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will be stored as ‘at risk’. For pancreatic cancer, if the person belongs to Ashkenazi Ancestry, 
then only one additional affected relative is needed to meet the criteria. 
The figures 6 and 7 show the procedures of family history analysis. The same steps that 
has been used for personal history analysis will be used to check the family history (only for 
first- or second-degree relatives) analysis.  
After collecting the information of already known or diagnosed gene mutation, the 
relative’s family history will be checked. For that, the flowchart collects the information about 
first- or second-degree relative’s personal history of breast cancer. Checking personal history of 
breast cancer has divided into four based on the age group. The information will be collected 
separately for different age category.  
After that, the flowchart checks if the person has a history of epithelial ovarian cancer. 
Next, it will check the presence of pancreatic and prostate cancer and also checks the male breast 
cancer history. If the person has a first- or second-degree relative with these cancers, the result 
will be stored and enter into next section.  
To check a third-degree relative’s family history, a different method has been followed. If 
a third-degree relative is identified with breast or ovarian cancer, the flowchart checks the 
number of other relatives who have identified with breast or ovarian cancer in the same side of 
the family. If there are more than two people identified with breast or ovarian cancer (one at least 
before the age of 50), the result will be stored as ‘at risk’. 
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5.1.2 Checking Tp53 mutation. 
 
Figure 8. Tp53 mutation analysis. 
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The figure 8 shows the procedures to check the Tp53 mutation. To begin with, the 
information will be collected if the person is already identified with Tp53 mutation. 
 In the next step, it checks whether the person meets classic-Li-Fraumeni syndrome 
criteria or not. In order to check the classic Li-Fraumeni syndrome criteria, the flowchart checks 
if the person is identified with a sarcoma before the age of 45. If the person is diagnosed with 
sarcoma, first- or second relative’s history of cancer before the age of 50 will be checked. If the 
first-, or second-degree relative is identified with cancer, it checks the additional relative’s 
history of cancer. The result will be stored as ‘at risk’ if all three criteria has been met.  
Next, the procedure enters into Chompret criteria section. Checking Chompret criteria 
starts from identifying individual with a tumor that belongs to LFS tumor spectrum before the 
age of 46. LFS tumor spectrum includes sarcoma, brain tumor, breast cancer, leukemia, 
adrenocortical carcinoma and lung Broncho alveolar cancer. Next, the relative’s history of LFS 
tumors (include breast primaries) will be checked if the individual is identified with LFS tumors. 
After that, it checks whether the individual is diagnosed with multiple tumors, and two of them 
belongs to LFS spectrum or not. If yes, the result will be stored as ‘at risk’. In the final step, the 
flowchart checks if the individual is diagnosed with adrenocortical carcinoma or Choroid plexus 
carcinoma. 
In the next step, the flowchart checks if the person is diagnosed with breast cancer before 
or at the age of 35-year-old. If the person meets the criteria, he/she is at risk of both Tp53 and 
BRCA gene mutation.  The result will be collected if the condition is satisfied, and enter into 
PTEN mutation analysis.  
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5.1.3 Checking PTEN mutation. 
 
Figure 9. PTEN analysis. 
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Figure 10. PTEN analysis (cont.). 
The figures 9 and 10 explain the procedures involved in PTEN mutation analysis. First of 
all, the flowchart checks if the person is already known or diagnosed PTEN gene mutation, and 
then the result will be collected. In next step, it checks if the individual is meeting clinical 
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diagnostic criteria for CS/PHTS and the information will be collected if the person has met the 
criteria. After that, it checks the personal history of Bannayan_Riley Ruvalcaba syndrome, and 
the information will be stored if it is identified. Next, the flowchart enter into checking of 
personal history of Adult Lhermitte Duclos disease, and the result will be stored if the person 
has/had a history of the disease. Then, it checks the personal history of autism spectrum disorder 
and macrocephaly condition. After that, it checks two or more biopsy-proven trichilemmomas. 
After collecting the result, it checks whether the person is meeting three major clinical diagnostic 
criteria without macrocephaly. Next, the flowchart enters into identification of two or more 
major criteria with macrocephaly or it checks whether the person has met one major criterion and 
more than three minor criteria. In the next step, the flowchart checks whether the individual 
meets more than four minor criteria or not. After that, the flowchart checks if any of the 
individual’s family member meets one major criterion and two or more minor criteria. The result 
will be stored if the criteria have been met. In final section, the result stored from different 
sections will be combined and displays the result based on the different combination of the 
result. The final output gives a separate report based on the three sections. 
5.2 Proposed Design 
The proposed block diagram of the program is shown in Figure 4. We have considered all 
the clinical possibilities, including inheritance pattern, family history assessments, and medical 
reports to generate the program. 
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Figure 11. Proposed design. 
As described earlier, this program has three sections (BRCA1/BRCA2 checking, Tp53 
checking and PTEN mutation checking). As shown in the above figure, the program analyzes 
personal history, family history and already known mutation condition. The program checks 
individual known mutation history, personal history, and family history for BRCA1/BRCA2, 
Tp53 and PTEN gene mutation. The result of each section will be stored separately, whenever 
the NCCN criteria are met. The program combines different section’s result and displays the 
result based on the analysis. The result will contain the risk of passing mutation risk or getting 
cancer in next generation. The family history includes, first, second and third-degree relatives 
health history. 
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Figure 12. A pedigree chart.  
We have considered family history that includes first-, second-, and third-degree 
relatives. The above figure 6 gives a detailed picture of first-, second-, and third-degree relatives. 
First-degree relatives include parents, siblings, and children. Second-degree relatives include 
grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings. Third-degree 
relatives include great-grandparents, great-aunts, great-uncles, great-grandchildren, and first 
cousins (Daly et al., 2014). The tool combines the personal history, family history, and known 
mutation history to detect the presence of faulty genes. In the output, the tool combines all the 
results from different sections and displays the results. 
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5.3 Software Tool to Predict Hereditary Breast Cancer in Current and Future Generation 
This software program was developed with JavaScript, HTML, and CSS.  
 
Figure 13. Image of the software program. 
Based on the guidelines, the program analysis is divided into three sessions: 1) Hereditary 
breast/ovarian cancer syndrome analysis, 2) Li-Fraumeni syndrome analysis, and 3) Cowden 
syndrome analysis.  
5.3.1 Hereditary breast and ovarian cancer syndrome analysis. As the first step, the 
program checks the breast and ovarian cancer syndrome (BRCA1/BRCA2 mutation).  This part 
of the program would check different criteria that are defined by NCCN to detect the presence of 
BRCA1/BRCA2 genes. Based on the NCCN guidelines, individuals from a family with known 
BRCA1 or BRCA2 mutation should be considered for testing. If the individual is not from a 
known gene mutation, the risk can check based on the testing criteria discussed below. Close 
relatives include first-, second- and third-degree relatives from the same side (paternal and 
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maternal side) of the family. If the individual has less than two first- or second-degree relatives 
can be considered as limited family history. The analysis has been divided into three sections: 1) 
an individual with an already known or diagnosed BRCA1/BRCA2 mutation, 2) checking 
personal history of different types of cancers, such as breast cancer, epithelial ovarian cancer, 
male breast cancer, pancreatic or prostate cancer, and Ashkenazi ancestry, and 3) checking 
family history of the person. The program checks personal and family histories to detect the 
presence of mutation. The tool also checks the presence of different hereditary cancers such as 
epithelial ovarian cancer, prostate cancer, pancreatic cancer, and male breast cancer, and it also 
checks ancestry (e.g., Ashkenazi Ancestry). The result will be stored if any criteria are met. 
5.3.1.1 Person with known mutation. This part will check whether the individual is 
already diagnosed with BRCA mutations or if he or she has a known personal/family history of 
BRCA1/BRCA2 mutation. If the person has a genetic report or medical report that identify the 
mutation of BRCA1/BRCA2 gene, she/he will be considered as at risk of developing breast 
cancer. The lifetime risk vary from 41% to 85%. If there is a history of already known 
BRCA1/BRCA2 mutation, the tool will consider the person as having met the NCCN criteria and 
will store the result as positive. 
5.3.1.2 Personal history.  In the next section, the program analyzes the personal history 
of cancers that related with BRCA1 and BRCA2 mutation. Checking personal history has been 
divided into four subsections: a) personal history of breast cancer, b) epithelial ovarian cancer, c) 
male breast cancer and d) pancreatic or prostate cancer. 
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Figure 14. Personal history-BRCA1/BRCA2 analysis. 
5.3.1.2.1 Personal history of breast cancer. The personal history of breast cancer has 
been divided into four different age groups: ages 45 and less, age less than or equal to 50, age 
less than or equal to 60, and diagnosed at any age. The tool considers the result positive (at risk) 
if any individual with a personal history of breast cancer meets any of the following criteria. 
 Diagnosed at the age of 45 or less: Hereditary breast cancers are likely to appear during 
early stages of life. Identifying breast cancer before or at the age 45 is an indication of 
inherited gene mutation. 
 Diagnosed at the age of 50 or less along with two breast primaries, one or more close 
relative with breast cancer at any age, or unknown family history. Primary breast cancer 
means that the breast cancer is not yet attacked other parts of the body. Women diagnosed 
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with a primary breast cancer is at higher risk of developing a second primary cancer in 
another breast. 
 Diagnosed at the age of 60 or less with triple-negative breast cancer. Triple-negative 
breast cancer is a term that use in pathology. In pathology reports the negative results 
mean that the cancer is not associated with HER2 (HER2-), estrogen receptors (ER-), and 
progesterone receptors (PR-). 
 Diagnosed at any age with any of the following:  
 One or more close relatives with breast cancer diagnosed at the age of 50 
years or younger,  
 A relative with epithelial cancer at any age,  
 Two or more relatives with pancreatic cancer or prostate cancer, 
 A close relative with male breast cancer,  
 Ashkenazi ancestry.  
  Ashkenazi Jewish people are originally from Central or Eastern Europe. They were 
geographically and genetically isolated people for centuries. Therefore, faulty genes might have 
been passed down through generations and as a result, put them more at risk. The lifetime risk of 
getting breast cancer is 90% for any person who belongs to Ashkenazi Jewish ancestry with 
mutated gene of BRCA. According to NCCN guidelines, if the patient is with personal history of 
breast cancer and with an Ashkenazi Jewish ancestry, no additional family history is needed to 
meet the criteria (Daly et al., 2014). 
5.3.1.2.2 Personal history of epithelial ovarian cancer. Germline mutations of 
BRCA1/BRCA2 genes are related to high risk of epithelial ovarian cancer (5% to 10%). A 
person diagnosed with epithelial cancer at any age will be at risk of hereditary breast cancer. 
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5.3.1.2.3 Personal history of male breast cancer. Personal history of male breast cancer 
can be considered a potential factor related to hereditary breast cancer. Men with breast cancer 
are more susceptible to BRCA2 gene mutation than BRCA1 mutation. The lifetime risk of breast 
cancer with BRCA2 gene is 6% by age of 70, and it is only 1% with the BRCA1 gene. 
5.3.1.2.4 Personal history of pancreatic or prostate cancer. Mutation in BRCA1 or 
BRCA2 contributes high risk of pancreatic and prostate cancer. Men with BRCA1 or BRCA2 
mutations have higher risk of developing prostate cancer. Both men and women with BRCA1 or 
BRCA2 mutations have higher risk of pancreatic cancer (NCI, 2015). Especially, BRCA2 
mutation exhibits higher risk than BRCA1 in prostate cancer with Gleason score greater than 
eight. Both genes are also associated with high risk of developing pancreatic cancer. As a result, 
the result will be “at risk” if the person has a personal history of prostate cancer or pancreatic 
cancer at any age, and has two or more close relatives with breast, ovarian, pancreatic, or 
prostate cancer. For pancreatic cancer, if the person belongs to Ashkenazi Jewish ancestry, only 
one additional affected relative is sufficient to make the person at risk (Daly et al., 2014 
The result of the personal history analysis will be stored and will continue to check 
family history. The table below contains different test cases that were created for this section.  
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Table 3  
Test Cases for Personal History-BRCA1/BRCA2 Analysis 
T
es
t 
ca
se
s 
Do have any 
family member 
with known  
hereditary breast 
cancer 
(BRCA1/BRCA2 
mutation)? 
Have you 
ever 
diagnosed 
with breast 
cancer? 
Personal history of breast cancer and 
belongs to: 
 
Do you have ever 
diagnosed with 
epithelial ovarian 
cancer? 
Do you 
have ever 
diagnosed 
with male 
breast 
cancer? 
Personal 
history of 
prostate 
cancer 
with any of 
the 
following: 
Belongs to 
Ashkenazi 
Jewish 
family 
Personal 
history of 
pancreatic 
cancer at any 
age with any 
of the 
following: 
E
x
p
ec
te
d
 r
es
u
lt
 
<
=
4
5
 o
ld
 
<
=
 5
0
 o
ld
 
<
=
6
0
 t
ri
p
e 
–
v
e 
at
 a
n
y
 a
g
e 
w
it
h
 
P1 Yes No          At risk 
P2 No Yes          At risk 
P3 No yes  additional 
primary 
       At risk 
P3 No Yes  >=1 
relatives 
with BC 
       At risk 
P4 No Yes  Unknown 
family 
history 
       At risk 
P5 No Yes          At risk 
P6 No Yes    >=1 close 
relatives with 
BC 
diagnosed at 
the age of 
<=50 old 
     At risk 
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Table 3 
Cont. 
P7 No Yes    >=2 relatives 
with breast 
cancer 
     At risk 
P8 No Yes    >=1 close 
relatives with 
epithelial OC  
     At risk 
P9 No Yes    >=2 relatives 
with 
pancreatic 
cancer 
     At risk 
P10 No Yes    >=2 relatives 
with prostate 
cancer 
     At risk 
P11 No Yes    close relative 
with male 
breast cancer 
     At risk 
P12 No Yes          At risk 
P13 No Yes          At risk 
P14 No Yes       >=2 
relatives 
with breast 
cancer 
  At risk 
P15 No Yes       >=2 
relatives 
with 
pancreatic 
cancer 
  At risk 
P16 No Yes       >=2 
relatives 
with 
prostate 
cancer 
  At risk 
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Table 3 
Cont. 
P17 No Yes       >=2 close 
relatives 
with 
epithelial 
OC  
  At risk 
P18 No Yes       One more 
additional 
relative 
  At risk 
P19 No Yes          At risk 
P20 No Yes         >=2 relatives 
with breast 
cancer 
At risk 
P21 No Yes         >=2 relatives 
with 
pancreatic 
cancer 
At risk 
P22 No Yes         >=2 relatives 
with prostate 
cancer 
At risk 
P23 No Yes         >=2 close 
relatives with 
epithelial OC  
 
At risk 
 
BC stands for breast cancer, OC stands for epithelial ovarian cancer, PC-pancreatic cancer, Prc-prostate cancer, MBC- Male 
breast cancer. All of these test cases are for people who are ‘at risk’, and any other conditions or combinations would give the result as 
‘not at risk ‘.    
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5.3.1.3 Family history. In the next section, the program checks the family history. The 
tool examines the family history and determines the risk based on the frequency of cancer 
appearing in first-, second-, or third-degree relatives. The output will be stored based on the 
analysis of the family history. This section has been separated into two subsections to qualify the 
different conditions for the diagnosis.  
5.3.1.3.1 First- or second-degree relatives. First or second-degree relatives who satisfy 
the conditions. The conditions are same as the criteria used for checking personal history, and it 
has been discussed earlier in the personal history section. 
5.3.1.3.2 Third-degree relatives. Third-degree relatives with breast cancer and or ovarian 
cancer with two or more close blood relative with breast cancer (one at least before the age of 
50) or ovarian cancer. 
 
Figure 15. Family history-BRCA1/BRCA analysis.
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Table 4  
Test Cases for Family History –BRCA1/BRCA2 Analysis  
T
es
t 
ca
se
s 
K
n
o
w
n
 m
u
ta
ti
o
n
 
1
st
/2
n
d
 d
eg
re
e 
re
la
ti
v
es
 w
it
h
 
b
re
a
st
 c
a
n
ce
r
 
the age at diagnosed Family History Third degree relative with 
Expected 
Result 
<=
45 <=50 <=60 any age 
E
p
it
h
el
ia
l 
O
C
 
Pancreatic Prostate 
A
sh
k
en
a
zi
 
Breast 
cancer 
Ovarian 
cancer 
1 Yes No 
          
At risk 
2 No Yes  
Additional 
primary 
        
At risk 
3 No Yes 
 
>=1 
relatives 
with BC 
        
At risk 
4 No Yes 
 
Unknown 
family 
history 
        
At risk 
5 No Yes 
  
Triple -
ve BC 
       
At risk 
6 No Yes 
   
>=1 close 
relatives 
with BC 
diagnosed 
at the age 
of <=50 old 
      
At risk 
7 No Yes 
   
>=2 
relatives 
with breast 
cancer 
      
At risk 
8 No Yes 
   
>=1 close 
relatives 
with 
epithelial 
OC  
      
At risk 
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Table 4 
Cont. 
9 No Yes 
   
>=2 
relatives 
with 
pancreatic 
cancer 
      
At risk 
10 No Yes 
   
>=2 
relatives 
with 
prostate 
cancer 
      
At risk 
11 No Yes 
   
close 
relative 
with male 
breast 
cancer 
      
At risk 
12 No Yes 
          
At risk 
13 No Yes 
          
At risk 
14 No Yes 
     
>=2 relatives 
with breast 
cancer  
   
At risk 
15 No Yes 
     
>=2 relatives 
with 
pancreatic 
cancer  
   
At risk 
16 No Yes 
     
>=2 relatives 
with prostate 
cancer  
   
At risk 
17 No Yes 
     
>=2 close 
relatives with 
epithelial OC   
   
At risk 
18 No Yes 
     
One more 
additional 
relative  
   
At risk 
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Table 4 
Cont. 
19 No Yes 
      
 
   
At risk 
20 No Yes 
      
>=2 relatives 
with breast 
cancer  
  
At risk 
21 No Yes 
      
>=2 relatives 
with 
pancreatic 
cancer  
  
At risk 
22 No Yes 
      
>=2 relatives 
with prostate 
cancer  
  
At risk 
23 No Yes 
      
>=2 close 
relatives 
with 
epithelial 
OC   
  
At risk 
24 No Yes         
>=2 relatives 
with ovarian 
cancer  At risk 
25 No Yes          
>=2 
relatives 
with breast 
cancer At risk 
 
The above test case are for family history section. The test cases checks different scenarios for different age groups. In all of 
the above conditions, the expected output is ‘at risk’. The result will be stored as the program enters the next section.  
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The risk of breast cancer increases if the person has close blood relatives with a history of 
breast cancer. The risk increases as the number of affected relatives increases and also varies 
with people’s race and ethnicity. The next section analyzes Li-Fraumeni syndrome (Tp53). 
5.3.2 Li-Fraumeni syndrome analysis. At this stage, the software tool checks the 
presence of Li-Fraumeni syndrome. Breast cancer is common in women with Li-Fraumeni 
Syndrome (LFS). This syndrome is associated with germline mutation of Tp53 gene. The related 
tumors and cancers associated with Li-Fraumeni Syndrome are soft-tissue sarcomas, 
osteosarcomas, premenopausal breast cancer, adrenal cortex, colon cancer, acute leukemia, and 
brain tumors. The core cancers related with LFS syndrome are sarcoma, adrenocortical 
carcinoma, breast cancer and brain tumors. Chompret criteria and Classic Li-Fraumeni 
Syndrome criteria are the two different criteria that have been widely used to check the Tp53 
mutation. The flowchart to check Tp53 mutation (Li-Fraumeni syndrome) is given in flowchart 
section b. The program can be divided into four parts based on different checking criteria. In this 
section, the software tool checks four different conditions: a) an individual with known 
mutations, b) classic Li-Fraumeni syndrome criteria, c) Chompret criteria, and d) early age onset 
criteria. The result will not be stored if the conditions are not met. However, in either condition 
(criteria met or not), the program will enter into the next section. The analysis has been done as 
follows: 
5.3.2.1 Individual from a family with known mutation. In this part, the program checks 
if the individual is from a family that is already known to have or is diagnosed with the mutation 
of Tp53. If the individual has an already identified the mutation of Tp53, then the program would 
consider the person at risk and enter into the next section after storing the result. According to 
NCCN guidelines, people who are already diagnosed with Tp53 gene mutations are at risk of 
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hereditary breast cancer. People who carry the Tp53 mutated gene have a 21% to 49% risk of 
developing breast cancer by the age of 30, and the lifetime cancer risk is 68% to 93%. 
5.3.2.2 Checking classic Li-Fraumeni Syndrome criteria. To meet NCCN criteria for 
classic Li-Fraumeni Syndrome Criteria, the person should satisfy all three conditions.  
 Individual is diagnosed with sarcoma ( cancer related to connective tissues) before the 
age of 45 years; and  
 Individual has a first-degree relative with cancer, and it was diagnosed before the age of 
45; and 
 Individual has one or more first- or second-degree relatives with cancer diagnosed before 
the age of 45 or with a sarcoma at any age. 
5.3.2.3 Checking Chompret criteria. This part the program analyzes three conditions 
given below. If any of the conditions are met, the output will be stored and the program will exit 
from the section. 
 Individual with a tumor from LFS tumor spectrum (soft-tissue sarcoma, osteosarcoma ( 
cancer develops in bone), brain tumor, breast cancer, adrenocortical carcinoma, leukemia, 
lung Broncho alveolar cancer) before 46 years of age, and one or more first- or second-
degree relatives with cancers that included in the LFS spectrum before the age of 56 
years or with multiple primaries at any age; or 
 Individual with multiple tumors and two of them belonging to LFS spectrum and 
diagnosed before the age of 46 years; or 
 If the individual was diagnosed with adrenocortical carcinoma (a cancer that begin at the 
outer layer of the adrenal gland) or choroid plexus carcinoma (tumor arises from brain 
tissues) at any age of onset, regardless of the family history. 
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5.3.2.4 Early-age-onset criteria. An individual diagnosed with breast cancer before the 
age of 35 years can be considered as a person at risk of Tp53 mutation. A person with breast 
cancer under the age of 30 and with a family history of one or more core cancers in first- or 
second-degree relative has a 100% chance of having the p53 mutation.  
 
Figure 16. Tp53 analysis. 
The above figure is a screenshot from the Tp53 mutation analysis. This section includes 
ten questionnaires to check the risk of mutated gene. Based on the user’s selections the program 
will check the risk of Tp53 mutation. The accuracy of Chompret criteria alone is 92%. However, 
the combination of classic Li-Fraumeni syndrome criteria and Chompret criteria exhibits 99% 
accuracy (Gonzalez et al., 2009). 
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Table 5  
Test Cases for Tp53 Analysis 
Test 
cases 
Indivi
dual 
from a 
known 
mutati
on? 
Have you 
ever 
diagnosed 
with 
sarcoma 
before the 
age of 45? 
Do you have 
a 1st degree 
relative 
diagnosed 
with cancer 
before the age 
of 45? 
Do you have 
a 1st or 2nd 
degree 
relative with a 
cancer before 
age 45 or 
sarcoma at 
any age? 
Please select if 
you have 
diagnosed with 
any (before the 
age of 46): 
Please select if 
you have 1st or 
2nd degree 
relative 
diagnosed with 
any (before the 
age of 56): 
Do you have 
diagnosed with 
any of the 
condition in the 
list before the age 
of 46? 
Have you ever 
diagnosed 
with: 
Breast 
cancer 
diagnosed 
before the 
age of 35? 
E
x
p
ec
te
d
 R
es
u
lt
 *
 
P1          At risk 
P2          Not at risk 
P3          At risk 
P4     Soft tissue 
sarcoma 
Brain tumor    At risk 
P5      Brain tumor    Not at risk 
P6     Osteosarcoma Leukemia    At risk 
P7     Breast cancer Soft tissue 
sarcoma 
   At risk 
P8     Adrenocortical 
carcinoma 
Leukemia    At risk 
P9     Leukemia Soft tissue 
sarcoma 
   At risk 
P10     Lung Broncho 
alveolar cancer 
Adreno cortical 
carcinoma 
   At risk 
P11      Leukemia Soft Tissue 
Sarcoma, Brain 
tumor 
  At risk 
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Table 5 
Cont. 
P12       Multiple breast 
tumors 
  Not at risk 
P13        Adrenocortical 
carcinoma 
 At risk 
P14        Choroid plexus 
carcinoma 
 At risk 
P15          At risk 
P16      Leukemia    Not at risk 
P17     Soft tissue 
sarcoma 
    Not at risk 
P18     Osteosarcoma     Not at risk 
P19     Breast cancer     Not at risk 
P20     Adrenocortical 
carcinoma 
    Not at risk 
P21     Leukemia     Not at risk 
P22     Lung Broncho 
alveolar cancer 
    Not at risk 
 
The above table includes different test cases followed for Tp53 analysis section.  
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5.3.3 Cowden syndrome analysis. In this part, the program checks PTEN (Cowden 
syndrome) mutation. Cowden syndrome is related to mutations in the PTEN gene. In order to 
calculate the risk, the flowchart will check four criteria. There are some major and minor criteria 
that should satisfy the person to be at risk. 
Major criteria include: 
 Breast cancer 
 Endometrial cancer – Cancer begins in the inner layer of the uterus.  
 Follicular thyroid cancer 
 Multiple GI hamartomas or ganglioneuromas – Cancer starts in the nerve cells 
 Macrocephaly (58 cm in adult women, 60 cm in adult men) – A condition in which the 
head circumference is larger than normal. 
 Macular pigmentation of glans penis 
 Mucocutaneous lesions with any of the following: 
o One biopsy-proven trichilemmoma (tumor begins in the hair follicle)  
o Multiple palmoplantar keratosis (abnormal thickening of palms and soles) 
o Multifocal or extensive oral mucosal papillomatosis ( a skin surface elevation) 
o Multiple cutaneous facial papules ( a skin disorder) 
Minor criteria include: 
 Autism spectrum disorder 
 Colon cancer 
 Three or more esophageal glycogenic acanthoses (white plaque found in esophagus ) 
 Lipomas – A tumor which is composed of body fat. 
 Mental retardation 
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 Papillary or Follicular variant of papillary thyroid cancer 
 Thyroid structural lesions 
 Renal cell carcinoma – A type of kidney cancer 
 Single GI hamartoma or ganglioneuroma 
 Testicular lipomatosis 
 Vascular anomalies 
 
Figure 17. PTEN analysis. 
The above figure is a screenshot of PTEN analysis section. As shown in the figure, the 
program checks individual known mutation history, personal history and family history. The 
major and minor criteria dropdowns include different clinical criteria for PTEN gene testing. The 
program determines the risk of mutation based on the selections that have been made by the user. 
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Table 6  
Test Cases of PTEN Analysis 
Test 
cases 
Are you 
already 
diagnosed or 
known 
mutation in 
PTEN gene 
Individual 
with a personal 
history of: 
Do you have any close 
relative with: 
Major Criteria: Minor Criteria: Expected Result 
P1      At risk 
P2  Bannayan-
Riley-
Ruvalcaba 
syndrome 
   At risk 
P3  Adult 
Lhermitte-
Ducolos 
diseases 
   At risk 
P4  Autism 
spectrum 
disorder and 
macrocepahly 
   At risk 
P5  Two or more 
biopsy-proven 
trichilemmoas 
   At risk 
P6    Breast cancer 
Endometrial cancer 
 At risk 
P7    Follicular thyroid cancer 
Multiple GI hamartomas or 
gangalloneuromas 
 At risk 
P8    Macrocephaly 
Macular pigmentation of 
glans penis 
 At risk 
P9    Mucocutaneous lesions and 
One biopsy-proven 
trichilemmoma 
 At risk 
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Table 6. 
Cont. 
P10    Mucocutaneous lesions and 
Multiple palmoplantar 
keratosis 
 At risk 
P11    Mucocutaneous lesions and 
Multiple cutaneous facial 
papules 
 At risk 
P12    Breast cancer Autism spectrum disorder, 
Colon cancer, 
Three or more esophageal glycogenic 
acanthoses, 
Lipomas 
At risk 
P13    Endometrial cancer Lipomas, 
Mental retardation, 
Colon cancer 
At risk 
P14    Follicular thyroid cancer Lipomas, 
Mental retardation, 
Colon cancer 
At risk 
P15     Autism spectrum disorder, 
Colon cancer, Lipomas, 
Mental retardation, 
Papillary or Follicular variant of papillary 
thyroid cancer 
At risk 
P16   Breast cancer 
Endometrial 
cancer 
  At risk 
P17   Multiple GI 
hamartomas or 
gangalioneuromas 
Macrocephaly 
  At risk 
  
The above table-6 include different test criteria for PTEN gene mutations. 
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The program has four sections: 1) individual from a family with an already known 
mutation, 2) individual meeting clinical diagnostic criteria, 3) individual with personal history 
and other NCCN criteria 4) individual with a close blood relative meeting NCCN criteria.  
5.3.3.1 Individual with an already known mutation. First the flowchart will check if the 
individual has a known mutation of PTEN gene. 
5.3.3.2 Personal history. Individual with a personal history of any of the following 
diseases: 
 Bannayan-Riley-Ruvalcaba syndrome (BRRS) 
 Adult Lhermitte-Ducolos diseases 
 Autism spectrum disorder and macrocepahly 
 Two or more biopsy-proven trichilemmoas 
 Two or more major criteria  
 Three major criteria, without macrocepahly 
 One major and more than three minor criteria  
 More than four minor criteria 
5.3.3.3 Family history. The program check the family history of close blood relatives 
with any one or more major criteria or two or more minor criteria. 
The test result will be stored before it enters into the next section. 
5.3.4 Forecasting cancer in future offspring. Every child inherits two copy from their 
parents; one from their mother and one from the father. BRCA1/BRCA2, Tp53 and PTEN genes 
are not associated with x-linked inheritance. Therefore, the mutations can be inherited from 
either parent. Offspring of the individual with any of these gene mutations can inherit the 
mutation. 
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As BRCA1, BRCA2, Tp53 and PTEN genes exhibit autosomal inheritance pattern, there 
are four possible combinations for the children’s gene copy.  As shown in figure 3, two of the 
four, or 50 percent, can inherit the mutated genes (aA, aA). The other 50 percent do not inherit 
the mutated genes (AA, AA). These four combinations are possible every time a pregnancy 
occurs. The gender of the children (whether they are sons or daughters) does not matter. The 
chance of getting normal child is 50/50 for each pregnancy. Consider a mother who carries 
BRCA1 mutated gene, and her partner carries normal genes. In each pregnancy, the chances of 
getting normal child is 50% and also chances of getting child with the abnormal gene is also 
50%. We are using this information to predict the chances of hereditary breast cancer in the 
offspring or the child to be born if the individual is analyzed at risk by this tool. 
5.3.5 Output. In the final session, the output from different sections will be combined 
and displayed along with the next generation’s risk. There will be different output based on the 
different sections. The result contains mutated gene risk and breast cancer risk. The result also 
displays the risk of passing mutated genes to next generation. In the output, it has been advised 
that the result is not a substitution for professional genetic test. If the individual is at risk, we 
recommend a discussion with an oncologist for better treatment. This program will have four 
different outputs as shown in below. The outputs are based on different gene mutations analysis. 
It includes BRCA1/BRCA2 analysis, Tp53 analysis, PTEN analysis and ‘not at risk’ situations. 
The user can print the result and consult an oncologist for further assessments and treatments. 
 
84 
 
 
 
Figure 18. Output – BRCA1/BRCA2 mutation. 
The above figure represents one of the output. In this scenario, the person has met family history 
criteria of HBOC syndrome analysis.  
 
Figure 19. Output – PTEN mutation. 
The above figure shows the analysis result from Cowden syndrome or PTEN gene mutation.  
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Figure 20. Output – Tp53 mutation. 
The figure- 15 is a screen image of the output of the program for a user who met the Tp53 
mutation criteria. 
 
Figure 21. Output – ‘not at risk’ case. 
The above figure represents the output for a user who does not meet any criteria. 
5.3.6 Features of the program. 
 Includes PTEN and Tp53 genes: This tool includes high-risk Tp53 and PTEN genes, and 
none of the existing breast cancer tools available consider these high risk genes. 
 Consider ovarian, prostate, pancreatic cancer history. 
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 Included Ashkenazi Jewish history. 
 Available to the public: Many of the existing tools are proprietary and are not available to 
the public. This tool is open source, and it will be available to the public. 
 User-friendly: This is a very easy-to-use software tool, and any person with basic 
knowledge in computer operation can easily use it. 
 Easy to understand: It is easily understood by people who have little breast cancer 
awareness. 
 Universal acceptance: This tool is designed based on NCCN guidelines, and it is not 
restricted to a set of people based on their demography or ethnic group. The guidelines 
have been developed in coordination with twenty-five global leading cancer centers. 
Most of the existing tools have been developed based on the data collected from a 
particular demography. 
 Includes third-degree relatives: Considers family history that includes first-, second-, and 
third-degree relatives. Many tools available are not considering third-degree relatives and 
family history. 
Early detection and screening would help to prevent the cancer or to find the disease at an 
early age. Taking drugs would prevent or delay cancer onset if you are at risk of hereditary breast 
cancer syndrome. For example, medicines such as Tamoxifen and Raloxifene lower the breast 
cancer risk in the general population (Moyer, 2013). Individuals at risk may choose to have 
surgery to reduce their risk. The individual at risk is strongly recommended to have breast or 
ovarian cancer screening, including mammograms, MRI exams, ultrasound, and breast exams, 
performed by a physician. 
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6 CHAPTER 6  
Future Work and Conclusion 
Predicting disease with computer modeling and mathematical analysis is becoming more 
popular. Combining all known diseases and diagnosis would help medical practitioners to 
determine and predict diseases in the current or next generations. As the years go by, family 
health history stored in computers provides better assessments, accuracy, and standardization in 
forecasting diseases. Computers could be trained to forecast and predict specific diseases. We 
want to integrate this tool with other common inherited diseases such as cystic fibrosis, Down 
syndrome, type 2 diabetes, inherited heart diseases, or other hereditary cancers, and that will help 
both common people and medical professionals. We want to build this prototype as a 
comprehensive computer application to predict most of the common inheritable and predictable 
diseases. We like to add more hereditary cancers and improve the existing program with other 
moderate risk genes such as PALB1, BRIP, and LKB1. We want to include the non-hereditary 
risk factors that are related to lifestyle and diet. We also like to work on all known hereditary and 
non-hereditary cancers and integrate them with this tool. In future, we are considering to 
integrate this application with smartphone applications. 
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